1. 206027536 一种混合药液原料用搅拌装置
CN
22.03.2017
B01F 7/16 Loading...
B01F 7/16
Loading...
201621009050.7
浙江康恩贝中药有限公司
金汉台
B01F 7/16
Loading...
本实用新型公开了一种混合药液原料用搅拌装置，包括空心壳体、支腿、箱盖、混合壳体、加热空间、排放管道、电动机、旋转轴、搅拌杆、控制器和加热片，所述空心壳体的底部设有支腿，空心壳体的顶部通过铰链连接箱盖，空心壳体的内部通过一组设置在空心壳体底部的排放管道固定一组混合壳体，空心壳体的内壁和混合壳体外表面之间形成加热空间，空心壳体的内壁和外表面分别设有加热片和控制器，箱盖的顶部固定一组电动机，且电动机的主轴固定一组贯穿箱盖，并延伸至混合壳体内部中心的旋转轴，旋转轴的端部固定一组搅拌杆。本实用新型，结构简单，通过控制搅拌时的温度，进而提高药物的混合率，加快混合速度，从而提高成品的质量加快生产效率。
2. 206032111 一种粘稠性药液生产用螺旋卸料装置
CN
22.03.2017
B65D 25/38 Loading...
B65D 25/38
Loading...
202016001011958
浙江康恩贝中药有限公司
金汉台
B65D 25/38
Loading...
本实用新型公开了一种粘稠性药液生产用螺旋卸料装置，包括管道式壳体、安装板、出料口、旋转轴、螺旋叶片、螺纹块和螺纹杆，所述管道式壳体的一端设有安装板，管道式壳体的内部为空心结构，空心结构的中心设有一旋转轴，旋转轴在位于管道式壳体内部的杆体上设有螺旋叶片，旋转轴的一端贯穿管道式壳体，且旋转轴和所述管道式壳体在贯穿部位设有密封垫圈，旋转轴在位于管道式壳体外部的一端连接有螺纹块，螺纹块的一端通过螺纹连接一组螺纹杆，管道式壳体的侧面上设有多组出料口。本实用新型，结构简单，该装置既可以通过电源进行工作，又可以通过手动形式进行工作，防止出现断电而不能工作的现象，此外，该装置有多个出料口，从而加速卸料。
3. 106507684 光刻设备、转移衬底的方法和器件制造方法
CN
15.03.2017
G03F 7/20 Loading...
G03F 7/20
Loading...
112015000031670
ASML荷兰有限公司
A·A·范伯兹康
G03F 7/20
Loading...
一种光刻设备包括：衬底台、曝光后处理模块、衬底处理机器人及干燥站。所述衬底台被配置成支撑衬底用于曝光过程。所述曝光后处理模块是用于在曝光后处理所述衬底。所述衬底处理机器人被配置成将所述衬底从所述衬底台沿着衬底卸载路径转移至所述曝光后处理模块中。所述干燥站被配置成从所述衬底的表面主动地移除液体。所述干燥站定位于所述衬底卸载路径中。所述干燥站定位于所述曝光后处理模组中。所述曝光后处理模块可以是晶片处理器。
4. 106408252 呈现针对当前位置或时间的信息
CN
15.02.2017
G06Q 10/10 Loading...
G06Q 10/10
Loading...
201610797599.5
谷歌公司
汤姆·卡尔·施塔姆
G06Q 10/10
Loading...
本发明涉及呈现针对当前位置或时间的信息。描述了一种计算系统，其至少部分地基于与计算设备的用户相关联的至少一个先前通信中所包括的信息获得未来位置和未来时间的指示以及与该未来位置和未来时间相关联的事件信息。该计算系统获得用户从计算设备的当前位置行进至该未来位置的持续时间，并且至少部分地基于该持续时间获得预测用户需要从当前位置出发以便在基于该事件的到达时间内到达未来位置的出发时间。该计算系统输出与该事件相关联并且包括指示该出发时间的信息的指示以便传输至该计算设备。
5. 106389180 一种银杏原花青素-多糖混合提取物及其制备方法和应用
CN
15.02.2017



201510454258.3
云南康恩贝植物研究院有限公司
乔洪翔


本发明提供一种银杏原花青素‑多糖混合提取物，该提取物中原花青素含量为40～60％，多糖含量为40～60％，原花青素和多糖总含量大于90％。本发明还提供制备上述提取物的制备方法，其包括下列内容：采用梯度乙醇水溶液提取、提取浓缩液加尿素二次提取、醇沉、沉淀分离多糖、醇沉液分离原花青素等步骤得到的提取物。本发明提供的银杏原花青素‑多糖混合提取物可作为用于抗氧化、抗辐射、美容抗衰老、癌症辅助治疗为目的的保健食品、药品或化妆品。
6. 104820029 一种复方鱼腥草合剂的含量检测方法
CN
25.01.2017
G01N 30/02 Loading...
G01N 30/02
Loading...
201510198172.9
浙江康恩贝中药有限公司
金汉台
G01N 30/02
Loading...
本发明公开了一种复方鱼腥草合剂的含量检测方法，该方法主要用水饱和正丁醇提取，上柱后水、醇洗脱，以Phenyl键合硅胶为色谱柱，流动相为乙腈‑0.5％乙酸溶液(体积比为18.5:81.5)；本发明提供的一种复方鱼腥草合剂的含量检测方法，不仅实现了解决了之前无法有效控制复方鱼腥草合剂特征成分槲皮苷的问题，而且同步检测复方鱼腥草合剂中槲皮苷、黄芩苷和连翘苷含量，保证了药品安全、有效、质量可控。
7. 106266129 一种蓝芩颗粒制备工艺
CN
04.01.2017
A61K 36/756 Loading...
A61K 36/756
Loading...
201610733924.1
浙江康恩贝制药股份有限公司
胡林水
A61K 36/756
Loading...
本发明公开了一种蓝芩颗粒制备工艺，包括以下步骤：（1）水煎；（2）醇沉；（3）喷雾干燥；（4）制粒。本发明对整个蓝芩颗粒制备工艺进行了优化改进，调整了原料配比，对水提、醇沉、喷雾干燥步骤的工艺参数进行了优化设计，并经严格筛选设计后限定了干燥助剂和辅料的种类和用量，解决了喷雾干燥时物料粘壁、结块的问题，步骤简单，工艺稳定，易实施，生产效率高，有效成分损失少，制得的颗粒粉质松脆，溶解性与流动性好，粉少，水分适宜。
8. 106248856 一种银杏叶制剂中有效成分的鉴别方法
CN
21.12.2016
G01N 30/90 Loading...
G01N 30/90
Loading...
201610412800.3
杭州康恩贝制药有限公司
徐春玲
G01N 30/90
Loading...
本发明公开了一种银杏叶制剂中有效成分的鉴别方法，包括如下步骤：(1)供试品的制备：取待测银杏叶制剂适量，加正丁醇提取、过滤，滤液蒸干，残渣加乙醇使溶解，作为供试品溶液；(2)对照品的制备：取银杏叶对照制剂适量，同步骤(1)，制备对照品溶液；(3)薄层色谱层析：吸取供试品溶液和对照品溶液各1～10μl，分别点样于同一硅胶G板，以乙酸乙酯、异丙醇、甲醇和水的混合物展开，取出薄板、空气中晾干，喷以1～5％三氯化铝乙醇溶液，置于365nm紫外光灯检视荧光，观察斑点。本发明提供的鉴别方法，各有效成分的分离效果好、斑点清晰、比移值适中，能够准确鉴别各有效成分，有利于定性分析和质量控制。
9. 106170218 用于组装用于烟制品的烟弹的方法
CN
30.11.2016
A24F 47/00 Loading...
A24F 47/00
Loading...
201580019489.X
RAI策略控股有限公司
弗雷德里克·菲利普·阿姆波立尼
A24F 47/00
Loading...
本公开涉及用于组装用于气溶胶递送装置的烟弹的系统、设备和方法。可以通过在将零件添加到基座的各种子站之间输送托架来组装所述烟弹。在另一组装方法中，可以在多个机器人之间移动所述基座，所述机器人将所述基座向下引导为与组件接触以使所述组件与其耦接。检查系统可以在各个完成阶段处检查所述烟弹。
10. 106164672 用于诊断的细胞表面前列腺癌抗原
CN
23.11.2016
G01N 33/574 Loading...
G01N 33/574
Loading...
112015000010766
麦诺米克国际有限公司
布拉德利·沃尔什
G01N 33/574
Loading...
本发明提供检测患者体液或组织中前列腺癌的组合物和方法。前列腺癌通过测量体液样品中磷脂酰肌醇蛋白聚糖‑1的水平来检测。在一个实施方式中，前列腺癌通过使体液样品与抗磷脂酰肌醇蛋白聚糖‑1抗体如MIL‑38接触来检测。发明包括用于体液样品中前列腺癌检测的试剂盒，其包括抗磷脂酰肌醇蛋白聚糖‑1抗体和磷脂酰肌醇蛋白聚糖‑1标准品。
11. 106165557 结构框架冷却歧管
CN
23.11.2016
H05K 7/20 Loading...
H05K 7/20
Loading...
112015000006852
约翰逊控制技术公司
康斯坦丁·波利索夫
H05K 7/20
Loading...
一种变速驱动装置包括连接至交流电源的转换器、连接至所述转换器的直流环节、以及连接所述直流环节的逆变器。所述逆变器将直流电压转换成具有可变电压和频率的输出交流电。所述逆变器包括至少一个电力电子器件模块和相关联的控制电路；与所述电力电子器件模块热连通并且与歧管流体连通的散热器。所述歧管包括具有流体连通的至少一个竖直构件部和至少一个水平构件部的管状构件。多个端口将冷却流体导入和导出所述歧管。托架将所述歧管联接至结构框架。提供托架以便将电力电子器件模块联接至所述歧管。
12. 106143033 用于机动车辆的悬挂装置
CN
23.11.2016
B60G 7/00 Loading...
B60G 7/00
Loading...
102016000319693
福特全球技术公司
雷纳·苏施莱克
B60G 7/00
Loading...
本发明涉及一种用于机动车辆的车轮悬挂装置(1、1a)，车轮悬挂装置(1、1a)至少包含纵向连杆(2、2a)，纵向连杆(2、2a)具有用于可枢转的车辆侧附接的第一端(5)和具有用于连接到轮架(3a)的第二端(6、6a)。为了提供在振动行为方面改进的较低重量的纵向连杆，根据本发明提供的是，纵向连杆(2、2a)至少部分地由纤维增强塑料制成。轮架(3a)与纵向连杆(2a)整体地形成，其中纵向连杆(2a)在第二端(6a)并入到轮架(3a)中。
13. 106063607 用于球类运动的鞋子
CN
02.11.2016
A43B 3/00 Loading...
A43B 3/00
Loading...
201610258510.8
阿迪达斯股份公司
罗伯特·弗兰克·科克
A43B 3/00
Loading...
描述的是用于球类运动的鞋子，其包括具有外表面的鞋面。配置执行器来改变所述鞋面的一部分外表面的至少一种表面性能，和配置传感器使其对于所述鞋子的移动敏感。将处理单元连接到所述执行器和所述传感器上，并且配置为处理获自所述传感器的传感器数据，并且如果在所述传感器数据中检测到预定的事件，则使得所述执行器改变所述鞋面的所述一部分外表面的至少一种表面性能。
14. 105965914 用于复合结构的自动层叠的装置和方法
CN
28.09.2016
B29C 70/38 Loading...
B29C 70/38
Loading...
201610139255.5
波音公司
M·R·德斯亚迪恩
B29C 70/38
Loading...
一种用于复合结构的自动层叠的装置和方法。一种用于将材料层(458)形成到成形工具(220)上的装置(200)可以包括至少一个鼻状件(552)，其被配置为将层板承载架(450)横向地扫到成形工具轮廓(236)上。该装置(200)可以包括一对张力臂(414)，其被配置为支撑层板承载架(450)的相对的横向侧(454)，该层板承载架(450)具有被安装到其下表面(452)的材料层(458)。该装置(200)可以包括一个或多个致动器(406、410)，其被配置为在将层板承载架(450)形成到成形工具轮廓(236)期间定位张力臂(414)。该一个或多个致动器(406、410)被配置为在将层板承载架(450)形成到成形工具轮廓(236)期间感测和控制层板承载架(450)中的横向张力(462)。
15. 104093933 挖掘工具的超硬尖端和包含其的挖掘工具
CN
14.09.2016
E21C 35/18 Loading...
E21C 35/18
Loading...
112012000069218
第六元素研磨剂股份有限公司
彼得·布什
E21C 35/18
Loading...
本发明涉及一种挖掘工具的冲击尖端，其包括含有超硬材料的冲击结构，该冲击结构在界面边界处连接至基层，且所述基层包含碳化物材料。所述冲击结构具有与界面边界相对的冲击端，所述冲击端包括圆形顶端，该圆形顶端具有至少3.2mm和至多6mm的纵断面曲率半径。
16. 103703539 带有辅助点火装置的高压放电灯
CN
17.08.2016
H01J 61/54 Loading...
H01J 61/54
Loading...
112012000036667
欧司朗有限公司
克劳斯·迈尔
H01J 61/54
Loading...
本发明涉及一种高压放电灯（1），包括放电容器（3）和辅助点火装置（2），该放电容器具有带有密封部的两个端部（4），电极（7）固定在该端部内。该辅助点火装置具有芯线（60），该芯线由压制成扁平的或者扁平的包裹线（61）缠绕。
17. 103610708 一种银杏根皮中低酸高纯度萜内酯提取物的制备工艺
CN
17.08.2016
C07D 493/22 Loading...
C07D 493/22
Loading...
102013000576700
浙江康恩贝制药股份有限公司
姚建标
C07D 493/22
Loading...
本发明公开了一种银杏根皮中低酸高纯度萜内酯提取物的制备工艺，以银杏根皮为原料，经粉碎至粗粉，加高浓度的乙醇提取，浓缩，加水稀释，经聚酰胺吸附树脂吸附洗脱，洗脱液浓缩，乙醇重结晶，得到的粗结晶经高效液相色谱分离，制得萜内酯提取物，其总内酯含量≥95%，总银杏酸含量≤1ppm。本发明方法克服了现有生产技术缺陷，具有生产工艺稳定可控、操作简便、产品质量高且稳定、成品得率高、生产成本较低等特点，且能将银杏根皮变废为宝，充分发挥其经济价值。
18. 103249727 联芳酰胺衍生物
CN
10.08.2016
C07D 305/08 Loading...
C07D 305/08
Loading...
112011000059302
霍夫曼-拉罗奇有限公司
约翰尼斯·埃比
C07D 305/08
Loading...
本发明提供具有通式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12和A如本文所述，并提供包含所述化合物的组合物和使用所述化合物的方法。
19. 105829681 用于航空器发动机的流体排出设备
CN
03.08.2016
F02C 7/232 Loading...
F02C 7/232
Loading...
112014000068556
涡轮梅坎公司
让-米歇尔·皮埃尔·克洛德·皮
F02C 7/232
Loading...
本发明涉及一种用于航空器发动机的流体排出设备(10)，该流体排出设备包括收集器(11)，该收集器被配置成收集从发动机排出的流体，其特征在于，所述设备包括用于泵送容纳在收集器中的流体和用于排放所述流体的装置(13，19)，所述设备还包括监测装置(14)，该监测装置被配置成发送由收集器收集的流体的异常收集的信号，所述监测装置被配置成当所收集的流体的流动大于泵送装置的流动时被激活。
20. 105745282 活性染料混合物，及其制备方法和应用
CN
06.07.2016
C09B 67/22 Loading...
C09B 67/22
Loading...
201480047979.6
德司达染料分销有限公司
罗克森纳·巴贝鲁
C09B 67/22
Loading...
本发明涉及染料混合物，所述的染料混合物包含至少一种通式(I)所示的染料和至少一种选自由式(IIa)?(IIf)所示染料组成的群组中的染料，及其制备方法与在纤维和纺织品染色中的应用。
21. 105651099 热交换器管板、热交换器以及制造热交换器管板的方法
CN
08.06.2016
F28F 9/04 Loading...
F28F 9/04
Loading...
201610035384.X
热矩阵集团有限公司
罗恩·波斯特马
F28F 9/04
Loading...
本发明涉及一种热交换器管板、热交换器以及制造热交换器管板的方法。所述热交换器管板(10)包括具有塑料主体部分的主体(20)，所述主体(20)包括多个通孔(26)，每个所述通孔(26)均由从所述主体(20)的第一主表面(22)延伸至相对的所述第二主表面(24)的周缘孔壁(28)限定，并且所述周缘孔壁(28)具有周缘凹槽(30)，并且其中，弹性的密封元件(32)被容纳在所述周缘凹槽(30)中，所述密封元件(32)从所述周缘凹槽(30)突伸到所述通孔(26)中，所述通孔(26′；26″)大致彼此平行地在所述主体(20)中延伸，并且其中，相邻通孔(26′；26″)的周缘凹槽(30′；30″)在所述通孔(26′；26″)的轴向上相对于彼此交错。
22. 105620464 用于优化自适应巡航控制中再生制动的系统和方法
CN
01.06.2016
B60W 10/08 Loading...
B60W 10/08
Loading...
201510810094.3
福特全球技术公司
布莱恩·托马斯·秀
B60W 10/08
Loading...
公开了一种用于优化自适应巡航控制中再生制动的系统和方法。一种车辆包括：牵引车轮；电机，被构造为向牵引车轮提供再生制动扭矩；车轮制动器，被构造为向牵引车轮提供摩擦制动扭矩；以及至少一个动力源，被构造为向牵引车轮提供驱动扭矩。所述车辆还包括：传感器，被配置为检测前方对象；以及至少一个控制器。控制器被配置为根据自适应巡航控制(ACC)算法来控制动力源、车轮制动器和电机。所述ACC算法被配置为响应于检测到的前方对象和最大的再生制动距离，命令电机提供再生制动扭矩而不应用车轮制动器。所述最大的再生制动距离是基于动力传动系统再生制动极限和距前方对象的距离而计算的。
23. 105637024 自润滑的药品注射器栓
CN
01.06.2016
C08K 3/38 Loading...
C08K 3/38
Loading...
201480057317.7
莫门蒂夫性能材料股份有限公司
萨穆尔·康佐恩
C08K 3/38
Loading...
一方面，提供了一种用于药品封装组件的自润滑部件。所述自润滑部件包含聚合物组合物和有效量的润滑添加剂例如，氮化硼。另一方面，可能提供一种药品封装组件，其具有用包含氮化硼的润滑组合物涂覆的表面。所述药品封装结构可能是，例如包含主体(筒体)和柱塞组件的预填充注射器。
24. 105593457 用于在流体调制器中产生压力信号的可移动元件
CN
18.05.2016
E21B 21/08 Loading...
E21B 21/08
Loading...
201480053680.1
普拉德研究及开发股份有限公司
S·A·科尔贝
E21B 21/08
Loading...
根据一个方面的流体调制器包括：本体，其在入口与出口之间形成流孔眼，所述流孔眼对于从所述入口轴向流动至出口的流体提供限流；以及可移动元件，其具有被布置成穿过所述本体的轴部以及可选择性地定位于所述流孔眼中以改变所述流孔眼的末端。
25. 105593099 用于将车钩杆铰接于轨道车辆的车体的轴承座
CN
18.05.2016
B61G 7/10 Loading...
B61G 7/10
Loading...
201480053262.2
沃依特专利有限责任公司
T·贝克
B61G 7/10
Loading...
本发明涉及用于将车钩杆铰接于轨道车辆特别是铁路车辆的车体的轴承座(1)。为了使所述轴承座(1)能够以能够简单且有效率地实现的方式适用于不同的用途，提供了模块化结构。为此目的，所述轴承座(1)包括：第一横向件(7.1)，该第一横向件(7.1)具有位于第一水平平面中的轴承壳体(3.1)；以及第二横向件(7.2)，该第二横向件(7.2)具有位于第二水平平面中的轴承壳体(3.2)。两个所述轴承壳体(3.1，3.2)在各自不同的情况下具有接口(4.1，4.2)，所述接口(4.1，4.2)用于垂直延伸(共同)的枢转螺栓或用于分配于对应的轴承壳体(3.1，3.2)的枢转销(54.1，54.2)。所述轴承座(1)的模块化结构特别地通过在所述轨道车辆的车体中以能够独立地彼此连接的独立的零件设置的所述第一和第二横向件(7.1，7.2)实现。
26. 205181991 适于固定至皮肤表面的输注装置
CN
27.04.2016
A61M 39/02 Loading...
A61M 39/02
Loading...
201490000510.2
贝克顿·迪金森公司
R·科尔
A61M 39/02
Loading...
一种适于固定至皮肤表面的输注装置，其包括可连接至皮肤表面的固定基体部件和可动部件。针或插管连接到可动部件并可相对于固定基体部件运动。可动部件可从第一位置运动到第二位置，在第一位置，针或插管不暴露于固定基体部件外部，在第二位置，针或插管暴露于固定基体部件外部。释放部件将可动部件保持在第一位置。移除释放部件允许可动滑动部件运动到第二位置。
27. 105480134 舒适托架的协调柔性支撑元件和柔性悬架部件
CN
13.04.2016
B60N 2/68 Loading...
B60N 2/68
Loading...
201510604672.8
福特全球技术公司
马克·席尔瓦·康德拉德
B60N 2/68
Loading...
一种车辆座椅支撑托架包括具有柔性主体部分的上部座椅靠背面板。第一组柔性悬架元件在第一方向上呈波浪形。第二组柔性悬架元件在总体上垂直于第一方向的第二方向上呈波浪形。下部座椅靠背面板可操作地连接到上部座椅靠背面板。下部座椅靠背面板包括限定中心孔的边缘元件和第一垫支撑件和第二垫支撑件。第一垫支撑件和第二垫支撑件中的每一个的中心部分包括多个柔性悬架元件。
28. 105453176 智能间隙填充框架内使用双声道处理的音频编码器、音频解码器及相关方法
CN
30.03.2016
G10L 21/0388 Loading...
G10L 21/0388
Loading...
201480041226.4
弗劳恩霍夫应用研究促进协会
萨沙·迪施
G10L 21/0388
Loading...
一种用于生成解码的双声道信号的设备，包括：音频处理器(802)，用于对编码的双声道信号进行解码以获得第一组第一频谱部分；参数化解码器(804)，用于提供第二组第二频谱部分的参数化数据以及提供用于标识第二频谱部分的第一双声道表示或不同的第二双声道表示的双声道标识；以及频率再生器(806)，用于取决于第一组第一频谱部分中的第一频谱部分、第二部分的参数化数据以及第二部分的双声道标识来再生第二频谱部分。
29. 205070688 电动汽车用驱动装置的冷却流道
CN
02.03.2016
H02K 9/00 Loading...
H02K 9/00
Loading...
201520891940.4
大陆汽车投资（上海）有限公司
马尔·贝恩德
H02K 9/00
Loading...
本实用新型提供一种电动汽车用驱动装置的冷却流道，所述驱动装置包括：电机和逆变器，所述电机由定子、转子、前盖、前壳体、中壳体和后盖依次配合组装而成，转子设置在定子内部，定子设置在中壳体内，还包括：下部冷却通道，设置在逆变器内部；上部冷却通道，设置在电机的前盖和前壳体密封配合而成的空间内；中部导流通道，其设置在中壳体的预订区域内，该中部导流通道的第一端连接在下部冷却通道，并且第二端连接在上部冷却通道。本实用新型提供的冷却流道可以应用制作工艺相对简单的挤压工艺，从而提高成品率，降低制造成本。
30. 105287657 一种治疗癫痫病的银杏叶提取物及其用途
CN
03.02.2016
A61K 36/16 Loading...
A61K 36/16
Loading...
201510468962.4
浙江康恩贝制药股份有限公司
单伟光
A61K 36/16
Loading...
本发明提供一种治疗癫痫病的银杏叶提取物，所述提取物的药效成分含总银杏萜内酯、总黄酮、原花青素，总银杏萜内酯含量10%~12%，总黄酮含量40%～44%，原花青素含量重量百分比45%~50%，总银杏萜内酯+总黄酮+原花青素>95%，总黄酮醇苷含量重量百分比24%～26%，且原花青素/总黄酮的含量重量比值为1.05~1.25，原花青素/总银杏萜内酯的含量重量比值为4.0~4.4。所述提取物可用于制备治疗癫痫持续性发作、癫痫后大鼠大脑内异常的痫性放电、癫痫引发的学习记忆障碍的药物。
31. 105308020 脲衍生物及其作为脂肪酸结合蛋白(FABP)抑制剂的用途
CN
03.02.2016
C07C 275/28 Loading...
C07C 275/28
Loading...
201480016538.X
豪夫迈·罗氏有限公司
贝恩德·布埃特尔曼
C07C 275/28
Loading...
本发明提供具有通式(I)的新型化合物，包括所述化合物的组合物和使用所述化合物的方法，其中R1、R2、R3、R4、W、A和B如本文所述。
32. 105264477 用于移动用户界面对象的设备、方法和图形用户界面
CN
20.01.2016
G06F 3/0485 Loading...
G06F 3/0485
Loading...
201480032749.2
苹果公司
N·赞贝蒂
G06F 3/0485
Loading...
一种具有显示器和触敏表面的电子设备显示具有多个内容单元的用户界面，其中沿用户界面中的第一轴布置内容单元，并且相应内容单元与对应元数据相关联。该设备检测触敏表面上的接触并检测该接触的第一移动。响应于检测到该接触的第一移动，该设备根据第一移动而垂直于用户界面中的第一轴移动第一组一个或多个内容单元，并且针对第一组内容单元中的一个或多个相应内容单元，该设备显示与刚检测到接触的第一移动之前未显示的相应内容单元相邻的相应内容单元的元数据。
33. 105168509 一种高含量复方鱼腥草合剂的制备工艺
CN
23.12.2015
A61K 36/78 Loading...
A61K 36/78
Loading...
201510415734.0
浙江康恩贝中药有限公司
王建方
A61K 36/78
Loading...
本发明公开了一种高含量复方鱼腥草合剂的制备工艺，以鱼腥草、黄芩、板蓝根、连翘和金银花为主药药材制备，该合剂含有的药效成分及其含量为：鱼腥草素10～25μg/ml、槲皮苷50～100μg/ml、黄芩苷1～2mg/ml、连翘苷15～40μg/ml；其制备步骤包括：(1)闪提；(2)水蒸气蒸馏；(3)醇沉；(4)水沉；(5)制剂。本发明提供的制备工艺，不仅可以有效提高复方鱼腥草合剂中鱼腥草素、槲皮苷等药效成分含量，而且能去除药材中的多糖、蛋白质、鞣制等成分，降低销售贮藏过程中产生的沉淀，提高了药物的稳定性和安全性，而且单独使用即可有效治疗外感风热引起的咽喉疼痛和急性咽炎、扁桃腺炎。
34. 105153014 用于治疗癌症的作为MDM2抑制剂的哌啶酮衍生物
CN
16.12.2015
C07D 211/40 Loading...
C07D 211/40
Loading...
201510205985.6
安姆根有限公司
M.D.巴特伯格
C07D 211/40
Loading...
本发明提供了式(I)的MDM2抑制剂化合物，其中变量如本文所定义，所述化合物可用作治疗剂，特别是用于治疗癌症的治疗剂。本发明还涉及含有MDM2抑制剂的药物组合物。
35. 105164104 脲衍生物及其作为脂肪酸结合蛋白(FABP)抑制剂的用途
CN
16.12.2015
C07D 205/04 Loading...
C07D 205/04
Loading...
201480016586.9
豪夫迈·罗氏有限公司
贝恩德·布埃特尔曼
C07D 205/04
Loading...
本发明提供具有通式(I)的新型化合物，包括所述化合物的组合物和使用所述化合物的方法，其中R1、R2、R3、R4、W、A和B如本文中所述。
36. 105144086 异构处理器装置和方法
CN
09.12.2015
G06F 9/38 Loading...
G06F 9/38
Loading...
201380062283.6
英特尔公司
P·纳凡兹
G06F 9/38
Loading...
描述了异构处理器架构。例如，根据本发明的一个实施例的处理器包括：大型物理处理器核的集合；小型物理处理器核的集合，这些小型物理处理器核具有相对于大型物理处理器核的相对较低的性能处理能力和相对较低的功率使用；虚拟到物理(V-P)映射逻辑，用于通过虚拟核的对应集合将大型物理处理器核的集合暴露给软件，并且对该软件隐藏小型物理处理器核的集合。
37. 105103122 异构处理器装置和方法
CN
25.11.2015
G06F 9/44 Loading...
G06F 9/44
Loading...
201380062284.0
英特尔公司
P·纳凡兹
G06F 9/44
Loading...
描述了异构处理器架构。例如，根据本发明的一个实施例的处理器包括：两个或更多小型物理处理器核的集合；至少一个大型物理处理器核，具有相对于小型物理处理器核的相对较高性能的处理能力和相对较高的功率使用；虚拟到物理(V-P)映射逻辑，用于通过虚拟核的对应集合将两个或更多小型物理处理器核的集合暴露给软件并且对该软件隐藏至少一个大型物理处理器核。
38. 105092453 对一种或多种材料进行测量的系统及方法
CN
25.11.2015
G01N 15/14 Loading...
G01N 15/14
Loading...
201510296034.4
卢米耐克斯公司
韦恩·D·罗特
G01N 15/14
Loading...
提供了对一种或多种材料进行测量的系统及方法。一种系统被配置为将一种或多种材料从一个或多个贮存容器转移至测量装置的成像空间。另一系统被配置为在测量装置的成像空间中对一种或多种材料成像。一种附加的系统被配置为在测量装置的成像空间中使一种或多种材料大致上固定不动。又一系统被配置为将一种或多种材料从一个或多个贮存容器转移至测量装置的成像空间、在所述成像空间中对所述一种或多种材料成像、在所述成像空间中使所述一种或多种材料或它们的某种组合大致上固定不动。
39. 105055330 一种盐酸文拉法辛长效缓释微丸及其制备方法
CN
18.11.2015
A61K 9/16 Loading...
A61K 9/16
Loading...
201510490075.7
杭州康恩贝制药有限公司
徐春玲
A61K 9/16
Loading...
本发明一种盐酸文拉法辛长效缓释微丸，包括：(1)第一缓释丸，由第一药丸和包衣于第一药丸表面的第一缓释层组成；(2)第二缓释丸，由第二药丸和包衣于第二药丸表面的第二缓释层组成；且第一缓释丸和第二缓释丸按1:1比例混合、胶囊灌装成总缓释微丸。本发明提供的盐酸文拉法辛长效缓释微丸，丸芯采用单一的微晶纤维素成分，选择适合黏度的乙基纤维素、适合的包衣量来分别制备第一缓释丸和第二缓释丸，并采用将药丸、缓释丸于流化床上一步制备的工艺，能够完美控制活性成分在2h、4h、8h、12h、24h等各时间点的药物释放量，持续、稳定。
40. 104997750 一种非洛地平缓释片及其制备方法
CN
28.10.2015
A61K 9/34 Loading...
A61K 9/34
Loading...
201510460601.5
杭州康恩贝制药有限公司
徐春玲
A61K 9/34
Loading...
本发明提供一种非洛地平缓释片，由缓释素片外包缓释层制得，缓释素片含有如下重量百分比的组分：非洛地平1～4％，增溶剂聚氧乙烯40氢化蓖麻油占2～8％，填充剂63～72.5％，粘合剂1～5％，骨架缓释材料10～25％，吸收剂1～6％，润滑剂0.2～1.5％；缓释层含有如下重量百分比的组分：包衣材料为乙基纤维素，增重为缓释素片总重的6～12％；增塑剂，增重为包衣材料重量的0～20％；抗粘剂，增重为包衣材料重量的0～50％；着色剂，增重为包衣材料重量的0～10％。本发明通过构建缓释素片和包衣缓释材料，实现制剂的双重缓释，充分释药，大幅提高生物利用度，符合一致性评价要求；且重现性好、均一性高，质量可控。
41. 204730479 带开关电源的燃气热水器的点火装置
CN
28.10.2015
F24H 9/20 Loading...
F24H 9/20
Loading...
201520414277.9
成都康恩贝电子有限公司
何宁
F24H 9/20
Loading...
本实用新型公开了一种带开关电源的燃气热水器的点火装置，包括集成一体的主控器、脉冲点火器和开关电源，所述主控器包括MCU单片机、点火器控制电路和火焰检测电路，所述的脉冲点火器分别通过点火器控制电路和火焰检测电路与MCU单片机连接，开关电源与MCU单片机连接，所述主控器还包括与MCU单片机连接的风机驱动电路、风机转速检测电路、电磁阀驱动电路、比例阀驱动电路和分段阀驱动电路。本实用新型具有功耗小、效率高、体积小、重量轻、稳压范围宽、精度高等特点，将热水器中的电源与控制器集成一体，不但提高了整机的稳定性，还简化了生成工序，节约了人力成本和物料成本。
42. 104971918 清洗工业设备部件以除去金属卤化物的方法
CN
14.10.2015
B08B 3/08 Loading...
B08B 3/08
Loading...
201510139808.2
瓦克化学股份公司
亚娃德·穆赫塞尼
B08B 3/08
Loading...
本发明涉及清洗工业设备部件以除去金属卤化物的方法。本发明提供了清洗工业设备部件以除去选自硅烷、金属卤化物、有机金属卤化物和它们的混合物中的污染物的方法，其中，所述方法包括用液态腈或胺或它们的混合物或用非质子溶剂中的腈或胺或它们的混合物的溶液处理工业设备部件。
43. 104970481 用于鞋的支承元件
CN
14.10.2015
A43B 5/02 Loading...
A43B 5/02
Loading...
201510158462.0
阿迪达斯股份公司
罗伯特·弗兰克·科克
A43B 5/02
Loading...
本发明涉及鞋的支承元件，尤其是足球鞋或美式橄榄球鞋，以及具有支承元件的鞋底和鞋。根据本发明的一方面，提供了鞋，尤其是足球鞋或美式橄榄球鞋，的支承元件。提供的该支承元件包含对应于从初始状态不会弯曲高达角度范围的临界值的弯曲的第一弯曲刚度，且其包含对应于超过角度范围的临界值的弯曲的第二弯曲刚度。其中，第二弯曲刚度大于第一弯曲刚度。
44. 104973602 在腈或胺存在下硅烷混合物的蒸馏
CN
14.10.2015
C01B 33/04 Loading...
C01B 33/04
Loading...
201510158284.1
瓦克化学股份公司
亚娃德·穆赫塞尼
C01B 33/04
Loading...
本发明涉及在腈或胺存在下硅烷混合物的蒸馏。本发明提供了一种在1013hPa下具有至少120℃的沸点的腈或胺或其混合物存在下蒸馏硅烷混合物的方法。本发明的方法实现了金属氯化物和有机金属卤化物更好的分离，其进而导致硅烷更高的产率和更少的浪费。
45. 204693846 带开关电源的热水器控制器
CN
07.10.2015
F24H 9/20 Loading...
F24H 9/20
Loading...
201520414028.X
成都康恩贝电子有限公司
何宁
F24H 9/20
Loading...
本实用新型公开了一种带开关电源的热水器控制器，包括集成一体的主控器、脉冲点火器和开关电源，所述主控器包括MCU单片机、点火器控制电路和火焰检测电路，所述的脉冲点火器分别通过点火器控制电路和火焰检测电路与MCU单片机连接，开关电源与MCU单片机连接。本实用新型具有功耗小、效率高、体积小、重量轻、稳压范围宽、精度高等特点，将热水器中的电源与控制器集成一体，不但提高了整机的稳定性，还简化了生成工序，节约了人力成本和物料成本。
46. 204689065 一种高速理瓶机
CN
07.10.2015
B65G 47/22 Loading...
B65G 47/22
Loading...
201520213601.0
浙江康恩贝集团医疗保健品有限公司
张爱军
B65G 47/22
Loading...
本实用新型公开了一种高速理瓶机，包括储料舱、提升机构、料桶、转盘系统、扫瓶机构、分瓶机构、理瓶机构、出瓶机构，所述提升机构由输送带与驱动电机组成，输送带下面安装有一只料桶，蹼轮安装在料桶出口处的底端，分瓶机构由输送带一与导瓶板组成，分瓶机构一侧设有两个主动轮，主动轮同一水平方向安装了从动轮，在主动轮与从动轮之间套有夹持带一，连接板一侧安装了五个升降台，升降台上依次安装有压瓶块一、压瓶块二、钩瓶器、压瓶轮一、压瓶块三与压瓶轮二，在夹持带一下面，安装了夹持带二，夹持带二尾端上面安装了夹持带三，夹持带三尾端上面安装有出瓶机构，在出瓶机构下面连接安装有一条输出带。
47. 204693984 一种药品风干输出装置
CN
07.10.2015
F26B 11/04 Loading...
F26B 11/04
Loading...
201520177447.6
浙江康恩贝集团医疗保健品有限公司
张爱军
F26B 11/04
Loading...
本实用新型公开了一种药品风干输出装置，包括风干机、转盘、滚筒、加强杆、安装板、合页装置、第二舱门、海绵、端盖、透明罩、第一舱门、盛料盒、震动箱、漏斗、输出管和变向装置，所述的风干机摆放在地面上，两转盘安装在风干机内部的齿轮上，两转盘之间固定有一滚筒，滚筒由网状金属围制而成，滚筒外围用螺丝固定有若干加强杆，滚筒正面设有安装板，并利用合页装置安装有第二舱门，滚筒内部固定有若干海绵，左转盘中心开有通孔与滚筒内部连通，且通孔外安装有端盖，风干机上安装有透明罩并将滚筒与转盘罩住，且透明罩正面设有第一舱门，震动箱上安装有盛料盒，盛料盒位于端盖底下，且震动箱左侧固定有输出管，输出管左端上方焊接连通有漏斗。
48. 204688450 一种自动数粒机
CN
07.10.2015
B65B 1/30 Loading...
B65B 1/30
Loading...
201520220699.2
浙江康恩贝集团医疗保健品有限公司
张爱军
B65B 1/30
Loading...
本实用新型公开了一种自动数粒机，一种自动数粒机，包括升降系统、料仓、三级振动盘供给系统、计数装置、落料系统、机身与底座，所述的升降系统由四组丝母丝杆组成，料仓正面设有观察窗，每两个观察窗设有一个出料窗，每个出料窗两侧装有两个齿条，齿条正面安装有操纵杆，料仓前面两侧安装了两条输送轨道，输送轨道内安装了输送板一、输送板二与输送板三并且互相叠加安装，输送轨道下面设有一个三级振动器，输送轨道末端设有下料通道，下料通道安装在计数装置内，在每个通槽的侧面安装了一个电子眼，下料通道末端设有料门，计数装置的一侧安装了落料系统，落料系统由下料斗、料门与料嘴组成，在落料系统外壳上安装手动式落料开关。
49. 204689088 一种药品输出变向装置
CN
07.10.2015
B65G 47/64 Loading...
B65G 47/64
Loading...
201520182677.1
浙江康恩贝集团医疗保健品有限公司
张爱军
B65G 47/64
Loading...
本实用新型公开了一种药品输出变向装置，包括震动箱、弹簧、固定架、盛料盒、挡门、漏斗、金属管一、输出管一、金属管二、支撑座、变向壳体、输出管二、变向槽和定位杆，所述的震动箱内安装有震动装置，且震动箱上左右各安装有两对弹簧，每对弹簧上均固定有一固定架，两固定架之间焊接有盛料盒，盛料盒的正面板上安装有可升降的挡门，挡门底下设有漏斗，漏斗与金属管一连通并利用金属管一固定于震动箱正面，金属管一尾端连接有输出管一，输出管一尾端连接有金属管二，变向壳体内部镂空，且其正面连通有三根不同朝向的输出管二，金属管二伸入到变向壳体内，且金属管二上端焊接有定位杆，定位杆卡入式安装在变向壳体上表面的变向槽内。
50. 204684198 一种软胶囊机
CN
07.10.2015
A61J 3/07 Loading...
A61J 3/07
Loading...
201520183013.7
浙江康恩贝集团医疗保健品有限公司
张爱军
A61J 3/07
Loading...
本实用新型公开了一种软胶囊机，包括机体、滚筒、输入杆、输入机构、模具安装座、固定板、安装架、毛刷、输出板、挡板、输出杆、升降台、螺杆、定位模块、注药模块，所述的机体正面左右分别安装有两滚筒与两输入杆，两输入杆底下分别设有两安装于固定板与机体之间的模具安装座，每一模具安装座中间设有转轴用于安装模具，毛刷与模具底面接触，两安装架底下设有斜向下的两输出板，两输出板之间分别固定有挡板，挡板上端设有输出杆，且两挡板之间留有空隙，机体上方设有升降机构，升降机构内安装有两螺杆，每一螺杆分别连接一定位模块，两定位模块底下连接安装有一注药模块，注药模块上端穿插有若干进料口，下端安装有两排喷嘴。
51. 204688965 一种瓶子输出装置
CN
07.10.2015
B65G 19/02 Loading...
B65G 19/02
Loading...
201520218196.1
浙江康恩贝集团医疗保健品有限公司
张爱军
B65G 19/02
Loading...
本实用新型公开了一种瓶子输出装置，包括舱体、输送带、料桶，其特征在于，所述的舱体顶端装有机舱盖，机舱盖下面设有两个液压杆，舱体底部安装有一个电子眼一，舱体左侧出口处安装了输送带，输送带上装有方形提升板，输送带顶端一侧通过传动轴安装了驱动电机，输送带顶端正面螺丝连接一导向槽，导向槽镶嵌在料桶上，料桶的一侧开有一个凹形缺口，料桶上端螺丝安装了悬挂杆，悬挂杆中间安装了拨片杆，料桶底部安装了上转盘与下转盘，料桶壁中间偏下部装有一个电子眼二，料桶缺口处设有一块透明塑料板，塑料板下面设有一个蹼轮，蹼轮与电机轴连接，电机与升降架通过螺杆连接。
52. 204693847 带开关电源的热水器恒温控制器
CN
07.10.2015
F24H 9/20 Loading...
F24H 9/20
Loading...
201520414060.8
成都康恩贝电子有限公司
何宁
F24H 9/20
Loading...
本实用新型公开了一种带开关电源的热水器恒温控制器，包括集成一体的主控器、脉冲点火器和开关电源，所述主控器包括MCU单片机、点火器控制电路和火焰检测电路，所述的脉冲点火器分别通过点火器控制电路和火焰检测电路与MCU单片机连接，开关电源与MCU单片机连接，所述主控器还包括与MCU单片机连接的出水温度检测电路和入水温度检测电路。本实用新型具有功耗小、效率高、体积小、重量轻、稳压范围宽、精度高等特点，将热水器中的电源与控制器集成一体，不但提高了整机的稳定性，还简化了生成工序，节约了人力成本和物料成本。
53. 104884002 SURGICAL HEART VALVES ADAPTED FOR POST IMPLANT EXPANSION
CN
02.09.2015
A61F 2/24 Loading...
A61F 2/24
Loading...
201380068269.7
爱德华兹生命科学公司
V·程
A61F 2/24
Loading...
A prosthetic heart valve configured to replace a native heart valve and having a support frame configured to be reshaped into an expanded form in order to receive and/or support an expandable prosthetic heart valve therein is disclosed, together with methods of using same. The prosthetic heart valve may be configured to have a generally rigid and/or expansion-resistant configuration when initially implanted to replace a native valve (or other prosthetic heart valve), but to assume a generally expanded form when subjected to an outward force such as that provided by a dilation balloon or other mechanical expander.
54. 104857259 一种贝母花提取物及其制备方法和应用
CN
26.08.2015
A61K 36/8966 Loading...
A61K 36/8966
Loading...
201410669600.7
浙江康恩贝制药股份有限公司
胡江宁
A61K 36/8966
Loading...
本发明提供了一种贝母花提取物及其制备方法和应用。本发明所述的贝母花提取物中贝母素甲与贝母素乙含量为提取物总量的20％-60％(w/w)。其用途为用于制备具有止咳化痰效果的药物或保健品。其制备方法包括：超声提取，滤液浓缩，碱化，葡聚糖凝胶柱分离，洗脱液浓缩干燥得贝母花提取物。该贝母花提取物制备方法操作简便，可有效富集贝母花有效成分，具有较好的开发应用前景。
55. 104447707 Hepatitis C virus inhibitors
CN
25.03.2015
C07D 403/14 Loading...
C07D 403/14
Loading...
201410607190.3
百时美施贵宝公司
C·巴查德
C07D 403/14
Loading...
The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
56. 104396284 Presenting information for a current location or time
CN
04.03.2015
H04W 4/02 Loading...
H04W 4/02
Loading...
201380032947.4
谷歌公司
汤姆·卡尔·施塔姆
H04W 4/02
Loading...
A computing system is described that obtains, based at least in part on information included in at least one previous communication associated with a user of a computing device, an indication of a future location and a future time and event information associated with the future location and the future time. The computing system obtains a duration of time for the user to travel from a current location of the computing device to the future location, and, based at least in part on the duration of time, obtains a departure time at which the user is predicted to need to depart from the current location in order to arrive at the future location by an arrival time based on the event. The computing system outputs, for transmission to the computing device, an indication associated with the event and including information indicative of the departure time.
57. 104161737 一种稳定的I晶型硫酸氢氯吡格雷片剂及其制备方法
CN
26.11.2014
A61K 9/30 Loading...
A61K 9/30
Loading...
201410430758.9
浙江金华康恩贝生物制药有限公司
胡江宁
A61K 9/30
Loading...
本发明涉及医药技术领域，公开了一种稳定的I晶型硫酸氢氯吡格雷片及其制备方法。本发明提供的I晶型硫酸氢氯吡格雷片中含有pH敏感性的粘合剂，其在不同pH的介质中溶出行为与上市产品一致，且其在生产和贮藏中稳定性好，保证了药物在服用中的临床有效性和安全性；其次，本发明提供的I晶型硫酸氢氯吡格雷片制备工艺简单，降低药品生产的成本，同时也解决了压片过程中出现的粘冲现象。
58. 104147054 一种银杏叶提取物及其制备方法和应用
CN
19.11.2014
A61K 36/16 Loading...
A61K 36/16
Loading...
201410389198.7
浙江康恩贝制药股份有限公司
乔洪翔
A61K 36/16
Loading...
本发明公开了一种银杏叶提取物及其制备方法和应用。本发明所述的银杏叶提取物中总银杏萜内酯的含量为6％～12％(w/w)，总黄酮含量为30％～70％(w/w)，原花青素含量为20％～60％(w/w)，总银杏萜内酯％+总黄酮％+原花青素％>90％，且总黄酮醇苷含量20％～50％(w/w)，其可作为制备用于预防或治疗神经系统疾病，如糖尿病性白内障、糖尿病性视神经病变或糖尿病性视网膜脂血症的食品、保健食品或药品。其制备方法包括：乙醇水溶液提取银杏叶，提取液浓缩至稠膏，冷水浸提稠膏，过滤后，滤液用大孔树脂吸附分离，洗脱液浓缩干燥后得银杏叶提取物。
59. 203915463 一种药品包装盒
CN
05.11.2014
A61J 1/00 Loading...
A61J 1/00
Loading...
201420109491.9
浙江康恩贝中药有限公司
陈卿
A61J 1/00
Loading...
本实用新型公开了一种药品包装盒，包括盒体和托架，盒体上连接有翻盖，托架包括固定面板和支承框架，固定面板连接在支承框架内，支承框架上设置有防阳光涂层，固定面板上开设有药品安装孔，固定面板的边缘开设有插销孔，翻盖上设置有与插销孔位置对应的插销，插销的顶端经折弯形成有倒扣，本实用新型通过由固定面板和支承框架组合形成托架，支承框架安装入盒体后，提高了接触面积，对于药品提到更好的保护，通过设置防阳光涂层，防止阳光透过包装盒体射至药品上，对药品起到更好的保护，通过采用插销进行盒体开口的封盖，改变以往采用外沿的方式，插销顶端设置倒扣后，锁合更加牢固，与现有技术相比，本实用新型具有防阳光，包装牢固的优点。
60. 104122363 一种甲钴胺片有关物质的测定方法
CN
29.10.2014
G01N 30/89 Loading...
G01N 30/89
Loading...
201410288671.2
杭州康恩贝制药有限公司
徐春玲
G01N 30/89
Loading...
本发明提供了一种甲钴胺片有关物质的测定方法，包括如下步骤：①供试品的制备：②对照品的制备；③采用高效液相色谱测定有关物质的含量，色谱条件为：固定相是以十八烷基硅烷键合硅胶为填料的色谱柱，流动相是由乙腈与磷酸盐缓冲液组成的混合液；检测波长为300～360nm，进样量为20μl，柱温为30℃，流速为0.5～1.5ml/min；梯度洗脱；④计算供试品中各杂质的含量。本发明提供的甲钴胺片有关物质的测定方法，通用性强、重现性好、分离度高、检测结果准确；经方法学验证表明，具有稳定性指示作用，能够快速、准确地实现甲钴胺片各杂质的限度控制，确保质量可控，而且该测定方法成本低廉，具有良好的经济效益和推广前景。
61. 103784448 Preparation method of natural 6-hydroxykynurenic acid extract and application thereof
CN
14.05.2014
A61K 31/47 Loading...
A61K 31/47
Loading...
201410007590.0
浙江康恩贝制药股份有限公司
王如伟
A61K 31/47
Loading...
The invention discloses a preparation method of a natural 6-hydroxykynurenic acid extract by separation from production waste water of a ginkgo biloba extract. The 6-hydroxykynurenic acid (6-HKA) extract is prepared through separation from the production waste water of the ginkgo biloba extract as a raw material. The preparation method comprises the steps: directly performing adsorption separation on the production waste water by using polyamide resin, and regulating a pH of an eluting concentrated solution and the like to prepare the 6-HKA extract. According to the preparation method, by fully utilizing folium ginkgo resources, the content of the 6-hydroxykynurenic acid in the extract is 50-90 percent, and the natural 6-hydroxykynurenic acid extract can be used for preparing foods, health foods or medicines for preventing or treating the nervous system disease, resisting the cardiovascular and cerebrovascular diseases or resisting depression.
62. 203512195 带外盖的奶粉包装罐
CN
02.04.2014
B65D 1/10 Loading...
B65D 1/10
Loading...
201320071129.2
浙江康恩贝健康产品有限公司
邵胜荣
B65D 1/10
Loading...
本实用新型涉及一种带外盖的奶粉包装罐。由罐筒体、罐底、带开口的罐顶、用于封闭该开口的内塞及套扣在罐顶侧的盖顶和盖圈一体的外盖所组成，在罐顶的开口边缘设有上凸的颈圈，塑料外盖内侧还设有与内塞外缘及罐体的罐顶开口颈圈外壁匹配套合的凸圈；罐体中位于罐顶内壁可以设置与罐体连接一体的密封膜。其罐顶的开口边缘设有上凸的颈圈，塑料外盖内侧加设与内塞外缘及罐体的罐顶开口颈圈外壁匹配套合的凸圈，提高了外盖的刚性强度，增加了外盖与罐体间的密封面，更有效地防止奶粉在运输或其它状态受到撞击等外力时，降低密封性而导致变质和对奶粉造成污染，并且食用阶段频繁开启，为方便取奶粉，去掉铁内盖，直接使用塑料外盖也能达到密封性好的贮藏要求。
63. 203501704 一种草药烘干设备
CN
26.03.2014
F26B 15/18 Loading...
F26B 15/18
Loading...
201320477080.0
建德市三都西红花专业合作社
王根法
F26B 15/18
Loading...
本实用新型提供一种草药烘干设备，包括草药的输送装置和沿输送方向布置的烘干单元，烘干单元设有烘箱，输送装置的输送带穿过烘箱内部，烘干单元包括烘箱的加热加湿装置，烘箱内设有温度和湿度传感器；烘干设备还包括分别与输送装置、加热加湿装置、温度和湿度传感器相连的控制装置。本实用新型以传送的方式将草药的烘干过程流程化，草药原材料由输送带送入烘箱进行烘干，并由输送带送出至收集斗进行收集，流程简单，操作方便，烘干效率高；并且烘箱在整个操作过程中始终保持恒温恒湿，既能达到很好的烘干效果，又能确保草药不被过度干燥引起变形甚至烘焦，烘干后的草药形状不会发生变化，外形美观，能最大程度地保持草药的有效成分含量。
64. 103622921 Pantoprazole sodium freeze-dried powder injection used for injection and preparation method thereof
CN
12.03.2014
A61K 9/19 Loading...
A61K 9/19
Loading...
201310385530.8
ZHEJIANG JINHUA CONBA BIO-PHARMACY CO., LTD.
TAN GUOJUN
A61K 9/19
Loading...
The invention relates to a pantoprazole sodium freeze-dried powder injection used for injection and a preparation method thereof. According to a freeze-drying method for the pantoprazole sodium freeze-dried powder injection used for injection, every 1000 bottles of the pantoprazole sodium freeze-dried powder injection are prepared by dissolving the components consisting of pantoprazole sodium, mannitol, calcium edentate/sodium edentate/sodium calcium edentate and citric acid in injection water to obtain drug liquid and freeze-drying the drug liquid, wherein before freeze-drying of the drug liquid, a proper amount of sodium hydroxide is used to adjust a pH value to 9.5 to 10.5. The preparation method comprises the following steps: 1) weighing; 2) preparation; 3) degerming and filtering; 4) bottle washing, drying and disinfection; 5) rubber plug cleaning, disinfection and drying; 6) filling; 7) freeze-drying and plug pressing; and 8) cover rolling. With such a technical scheme, the preparation method enables sublimation and drying time to be saved, energy consumption to be reduced and product quality to be guaranteed.
65. 103610708 Preparation technology of low-acidity and high-purity terpene lactone extract in gingko root and bark
CN
05.03.2014
A61K 36/16 Loading...
A61K 36/16
Loading...
201310576700.0
ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.
YAO JIANBIAO
A61K 36/16
Loading...
The invention discloses a preparation technology of a low-acidity and high-purity terpene lactone extract in gingko root and bark. The technology comprises the following steps: by taking gingko root and bark as raw materials, crushing into coarse powder; adding high-concentration ethanol to extract, concentrating, adding water to dilute, adsorbing by polyamide adsorption resin and eluting; concentrating an eluate, recrystallizing by ethanol, and separating the obtained coarse crystal by high-performance liquid chromatography, so as to prepare the terpene lactone extract, wherein the total lactone content is greater than or equal to 95%, and the total ginkgo acid content is smaller than or equal to 1ppm. By adopting the method disclosed by the invention, the defects of the existing production technology are overcome, and the method has the characteristics of being stable and controllable in production technology, simple and convenient to operate, high and stable in product quality, high in product yield, low in production cost and the like; the gingko root and bark can be changed into precious resources, so as to fully exert the economical value.
66. 103597374 Transparent glass scintillators, methods of making same and devices using same
CN
19.02.2014
G01T 1/20 Loading...
G01T 1/20
Loading...
201280025783.8
佐治亚技术研究公司
康智涛
G01T 1/20
Loading...
Compositions and methods are described for transparent glass composite having nanoparticles therein that scintillate in the presence of nuclear radiation, particularly gamma rays, but also x-rays, alpha particles, beta particles, and neutrons. The transparent glass composites can be prepared by a melt/cool process to produce the transparent glass composite. The wavelength of light emitted by the transparent glass composite can be tailored based on the materials used to make the glass composite. A detector that utilizes the transparent glass composite can measure nuclear radiation from numerous sources of radiation.
67. 203392089 内塞外盖组合一体奶粉罐
CN
15.01.2014
B65D 1/10 Loading...
B65D 1/10
Loading...
201320071162.5
浙江康恩贝健康产品有限公司
邵胜荣
B65D 1/10
Loading...
本实用新型涉及一种内塞外盖组合一体奶粉罐，由罐体、罐底、罐顶、内塞、外盖所组成，罐体中位于罐顶内壁侧还设有与罐体连接一体的密封膜，罐顶开口边缘有上凸的颈圈，内塞及外盖为组合一体件，其盖圈与罐筒体、内凸圈与罐顶颈圈外侧、内塞与罐顶颈圈内侧均形成密封，内塞与盖顶间的空腔还能放置干燥剂，因增设了密封膜，可保证完全密封和分辨销售过程消费者买到的是未开启的产品，增加了外盖与罐体间的密封面，既提高密封性也增加了盖的刚性和强度，更能有效防止奶粉运输等状态受外力或撞击时降低密封性而导致变质，尤其一体盖省去了频繁的二次开启和闭合，并能延长开启后的贮藏时间，一体盖的盖顶面上设置了与罐顶颈圈对应位置的凸环，引导用户盖合施力至准确位置，盖合快捷。
68. WO/2014/000599 DRY PREPARATION PROCESS OF INFANT FORMULA MILK POWDER
WO
03.01.2014
A23C 9/152 Loading...
A23C 9/152
Loading...
PCT/CN2013/077624
ZHEJIANG CONBA HEALTH PRODUCT CO., LTD
SHAO, Shengrong
A23C 9/152
Loading...
A microencapsulation preparation process of infant formula milk powder, comprising dried skim milk, whey powder, whey proteins, vegetable oil and fat, lactose, vitamins, mineral substances and other nutrients. A preparation method of the infant formula milk powder comprises the following steps of: using a microencapsulation technique to embed oils in the vitamins, the mineral substances, the vegetable oil and fat and the other nutrients; thoroughly mixing embedded vitamin powder, mineral substance powder, oil nutrients and powder iron composites and other nutrients with a dosage less than 5%; thoroughly mixing the composite obtained through the foregoing steps with the dried skim milk, the whey powder, the whey protein powder, lactose, vegetable fat powder and the like; and eventually nitrogenizing and packaging quantitatively.
69. 203365346 全自动灯检机合格品排出口导块
CN
25.12.2013
G01N 21/90 Loading...
G01N 21/90
Loading...
201320386110.7
浙江康恩贝制药股份有限公司
沈敏智
G01N 21/90
Loading...
全自动灯检机合格品排出口导块，包括上块（1）、下块（3），其特征在于，包括上块（1）底部装有一块档条（2），下块（3）中部往内加工出一道凹槽，凹槽上贴有润滑带（4）。所述润滑带（4）为润滑胶带。本实用新型创造能提高产品制成率。
70. 203360203 处理含有三氯甲烷废液的装置
CN
25.12.2013
C02F 9/10 Loading...
C02F 9/10
Loading...
201320386111.1
浙江康恩贝制药股份有限公司
张福康
C02F 9/10
Loading...
处理含有三氯甲烷废液的装置，其特征在于，包括加热器（1）、锥形瓶（2）、塑胶管（3）、冷凝器（4）、收集瓶（5），加热器（1）上装有锥形瓶（2），锥形瓶（2）通过塑胶管（3）连接有冷凝器（4），冷凝器（4）下面装有收集瓶（5）。所述加热器（1）一般为电加热器。本实用新型对三氯甲烷加以回收降解。有效控制污染，环境意义大。
71. 103459567 Composition comprising zwitterionic geminal liquids as wettability modifiers in improved oil recovery processes
CN
18.12.2013
C07C 229/26 Loading...
C07C 229/26
Loading...
201180064989.7
墨西哥石油研究院
R.赫南德兹阿尔塔米拉诺
C07C 229/26
Loading...
The invention relates to the use of zwitterionic geminal liquids of type bis-N-alkyl polyether or bis-N-alkenyl polyether or bis-N-aryl polyether bis-beta imino acids or the salts thereof as modifiers of the wettability of rock, such as limestone, dolomite, sandstone, quartz or heterogeneous lithologies, in the presence of brine having a high concentration of divalent ions, such as calcium, magnesium, barium and strontium, at a high temperature and pressure, in improved oil recovery processes.
72. 103328436 新芳基-苯并环烷基酰胺衍生物
CN
25.09.2013
C07C 237/24 Loading...
C07C 237/24
Loading...
201280006321.1
霍夫曼-拉罗奇有限公司
约翰尼斯·埃比
C07C 237/24
Loading...
本发明提供具有通式(I)的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A1、A2和n如本文所定义，包含所述化合物的组合物和使用所述化合物的方法。
73. 103271210 阿胶核枣糕
CN
04.09.2013
A23G 3/48 Loading...
A23G 3/48
Loading...
201310243026.4
浙江康恩贝集团医疗保健品有限公司
张爱军
A23G 3/48
Loading...
阿胶核枣糕，其特征在于：按重量百分比包括如下组分：阿胶21.8%、黑芝麻17.4%、冰糖17.4%、核桃仁13.0%、黄酒13.0%、红枣10.4%、金银花提取物0.2%、菊花提取物0.2 %、莲子粉3.3%、百合粉3.3%。本发明是一种以阿胶为主要原料，经溶化、浓缩等工艺加工而成。本发明清凉去火、适合于夏季食用。
74. 103282380 红细胞结合性治疗剂
CN
04.09.2013
C07K 14/47 Loading...
C07K 14/47
Loading...
201180048989.8
洛桑聚合联合学院
J.A.哈贝尔
C07K 14/47
Loading...
描述了特异性结合红细胞的肽。这些以具有特异性结合红细胞的序列的肽配体，或者以提供对红细胞的特异性结合的抗体或其片段提供。所述肽可以作为与治疗剂、耐受化抗原、或靶向肽的分子融合物制备。可以通过使用融合物及选择物质上期望得到耐受性的抗原来创建免疫耐受性。与靶向肽的融合物将融合物引导至靶物，例如肿瘤，在那里红细胞结合性配体通过将红细胞募集至靶物来降低或完全消除对肿瘤的血流。
75. 103283129 具有封闭的、自给自足的冷却介质循环的电机
CN
04.09.2013
H02K 9/19 Loading...
H02K 9/19
Loading...
201180062215.0
西门子公司
康拉德·布兰德尔
H02K 9/19
Loading...
一种电机：具有基体（1）、转子轴（6）和换热器（10）。该基体（1）包括至少一个定子（2）。在基体中布置有用于液态的冷却介质的冷却通道（4）。转子轴（6）这样安装在基体（1）中，即，转子轴可以围绕旋转轴线（5）旋转。转子轴（6）构造成能由液态的冷却介质流过的空心轴。换热器（10）用于将液态冷却介质中所含有的热量释放到电机周围环境中。换热器（10）、转子轴（6）和冷却通道（4）流动技术地、成对地相互连接，从而为液态的冷却介质产生封闭的循环。在转子轴（6）上抗扭地布置有输送元件（11），该输送元件连接在用于液态的冷却介质的封闭循环中，并且借助该输送元件强制液态的冷却介质在转子轴（6）围绕旋转轴线（5）旋转时在液态的冷却介质用的封闭循环中循环。
76. 103270473 用于定制显示关于媒体资产的描述性信息的方法
CN
28.08.2013
G06F 3/00 Loading...
G06F 3/00
Loading...
201180062511.0
汤姆逊许可公司
瓦西尔·纳德扎科夫
G06F 3/00
Loading...
本公开涉及显示多个窗口的用户界面，其中每个窗口在被激活时呈现关于媒体资产的描述性信息。该描述性信息本身可以是其它媒体资产(视频、音频、文本、图片、计算机程序)或可以是描述性信息字段(资产概要、导演、演员、工作室、电视信息、电影信息、音乐信息、音乐艺术家、艺术家、制片人、摄影导演、剧本作者、执行制片人、制片人、类型以及发布日期)。可以改变窗口的布置，使得通过这种改变来影响对描述性信息的后续显示。通常该改变将添加或删除对描述性信息字段或作为描述性信息媒体资产的其他资产的呈现。
77. 103249727 新的联芳酰胺衍生物
CN
14.08.2013
C07D 305/08 Loading...
C07D 305/08
Loading...
201180059302.0
霍夫曼-拉罗奇有限公司
约翰尼斯·埃比
C07D 305/08
Loading...
本发明提供具有通式(I)的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12和A如本文所述，并提供包含所述化合物的组合物和使用所述化合物的方法。
78. 103228681 包含侧链乙烯基的磷离子交联聚合物及其制备方法
CN
31.07.2013
C08F 8/40 Loading...
C08F 8/40
Loading...
201180056489.9
朗盛公司
格雷戈里·J·E·戴维森
C08F 8/40
Loading...
本发明涉及离子交联聚合物，包含在卤化异烯烃共聚物和包含至少一个侧链乙烯基的至少一种基于磷的亲核试剂之间反应的反应产物。本发明还涉及制备和固化这些离子交联聚合物的方法。
79. 103202483 一种补钙营养组合物
CN
17.07.2013
A23L 1/304 Loading...
A23L 1/304
Loading...
201210007318.3
浙江康恩贝健康产品有限公司
邵胜荣
A23L 1/304
Loading...
本发明涉及一种补钙营养组合物。包含矿物质钙、磷和ω-3不饱和脂肪酸，钙∶磷为1.3—2.5∶1；钙∶ω-3不饱和脂肪酸为1∶0.2—4；矿物质钙源为乳矿物盐、碳酸钙、葡萄糖酸钙、氨基酸螯合钙、磷酸钙、磷酸氢钙、乳酸钙中的一种或几种，矿物质磷源为：包括乳矿物盐、磷酸钙、磷酸氢钙中的一种或几种。其加上药学上或食品上可接受的载体制成各种口服液体制剂剂型或固体、半固体制剂。这样组合使三者营养物各自功效充分发挥，而且相互之间有协同增效作用，提高了钙在机体的吸收率，增加了钙的生物利用率，使食用者在停止补充本营养组合物后较长时间内仍具有良好成骨效应而不逆转，尤其是克服了现有钙制剂易导致结石的弊端，实现了补钙时不会引起肾（或泌尿系）结石的功效。
80. 103189085 自润滑的药品注射器栓
CN
03.07.2013
A61M 5/315 Loading...
A61M 5/315
Loading...
201180047872.8
莫门蒂夫性能材料股份有限公司
萨穆尔·D·康佐恩
A61M 5/315
Loading...
一方面，提供了一种用于药品封装组件的自润滑部件。所述自润滑部件包含一种聚合物组合物和有效量的润滑添加剂例如，氮化硼。另一方面，可能提供一种药品封装组件，其具有用包含氮化硼的润滑组合物将其包覆的表面。所述药品封装结构可能是，例如包含主体(筒体)和柱塞组件的预填充注射器。
81. 103115892 应用近红外光谱分析技术制备银杏叶提取物的方法
CN
22.05.2013
G01N 21/35 Loading...
G01N 21/35
Loading...
201310025331.6
浙江康恩贝制药股份有限公司
王如伟
G01N 21/35
Loading...
应用近红外光谱分析技术制备银杏叶提取物的方法，通过在对大孔树脂分离纯化过程中进行取样时，用近红外光谱建立模型，控制乙醇解析过程中有效成分收集的起点与终点,具体包括下述步骤：a样品的准备、b.银杏叶黄酮含量的检测、c.建立模型：光谱预处理、获取近红外光谱、模型的创建d.模型验证,e.结果分析，主要以考虑银杏黄酮的含量变化为主；本发明测定方法简单，速度快，样品无需处理，只需扫描出图谱，然后调用样品模型对待测成分含量进行预测即可，可以实现银杏提取过程即时分析和在线控制。
82. 103040690 水溶性杭白菊提取物的制备方法
CN
17.04.2013
A61K 8/97 Loading...
A61K 8/97
Loading...
201310025359.X
浙江康恩贝制药股份有限公司
王如伟
A61K 8/97
Loading...
一种水溶性杭白菊提取物的制备方法，包括以下步骤：a.将杭白菊用纱布分袋扎好，加入质量为杭白菊15倍的水提取，过滤，合并两次滤液；b.将两次滤液浓缩至浸膏；c.趁热过滤，滤液冷藏过夜；d.观察滤液澄清度，若已澄清，可直接用于干燥，干燥后提取物过80目筛，得到最终产物；最终得到水溶性杭白菊提取物含有绿原酸，黄酮类，挥发油，氨基酸，多糖类，微量元素，得率范围在（5-20）%。本发明的提取溶剂成本低，不会残留有机溶剂，提取的杭白菊提取物水溶性良好，在室温（20℃）时溶解度在10克以上（即易溶于水）。
83. 103044256 杯芳烃和包含杯芳烃的光致抗蚀剂组合物
CN
17.04.2013
C07C 69/76 Loading...
C07C 69/76
Loading...
201210496911.9
罗门哈斯电子材料有限公司
V·简恩
C07C 69/76
Loading...
分子玻璃化合物包括式C(R1)2＝C(R2)-O-(L)n-Ar1的芳族乙烯基醚与杯[4]芳烃的乙烯基醚加合物，其中R1和R2各自独立地为单键、H、C1-20烷基、C1-20卤烷基、C6-20芳基、C6-20卤芳基、C7-20芳烷基、或C7-20卤代芳烷基，L为C1-20连接基团，n为0或1，Ar1是含卤单环、或取代的或非取代的多环或稠合多环C6-20含芳族基团的基团，其中，当R1和R2任一个或两者为单键且n为0时，R1和R2连接到Ar1。还公开了包含所述分子玻璃化合物、溶剂、以及光致酸产生剂的光致抗蚀剂，包括(a)在其表面上具有待图案化的一个层或多个层的基材，和(b)在待图案化的一个层或多个层上的光致抗蚀剂组合物层的涂覆基材。本发明还公开了形成所述分子玻璃化合物的方法。
84. 103038044 形成座椅靠背的制造方法
CN
10.04.2013
B29C 45/16 Loading...
B29C 45/16
Loading...
201180025996.6
霍沃思公司
T.富克斯
B29C 45/16
Loading...
一种改进的座椅靠背，由采用模制材料的多次模制喷射的模制结构形成，从而在座椅靠背的选定区域中形成不同的性能特征。座椅靠背具有整体模制面板的外观，但是由多模制喷射形成，所述模制喷射优选在模制工具上的多个站处进行。通过提供多模制喷射和选定的材料以形成座椅靠背的不同区域，产生不同的性能特征，包括提供：给座椅靠背提供结构刚性的周边框架、给座椅占用者的腰部区域提供局部支撑的腰支撑面板，以及薄板状支撑面板，该薄板状支撑面板在框架之间延伸并且包围被限定在周边框架之间的内部区域以提供更柔性和顺从表面，从而提供与占用者后背更舒适的接触。
85. 103007199 一种莪术挥发油包合物的制备方法
CN
03.04.2013
A61K 36/9066 Loading...
A61K 36/9066
Loading...
201210580713.0
浙江康恩贝制药股份有限公司
胡林水
A61K 36/9066
Loading...
本发明涉及一种莪术挥发油包合物的制备方法。具体：取10倍量的纯化水a；取莪术油，加入莪术油1/5倍量的乙醇，得b；先用75%乙醇对胶体磨消毒，控制转速1500～3500rpm，再将b入胶体磨中，用a冲洗胶体磨内浆液，至出水呈无色，得c；取莪术油6倍量的β-环糊精，加a余下量，混入加热溶解后,冷至40℃～50℃，得d；将c缓慢加至d中,边加边搅拌,搅拌速度1000～2000rpm,加完后继续搅拌30min～45min，再置于0℃～4℃环境中冷藏、静置12h；然后抽滤至干，再用少量乙醇洗涤沉淀，滤液弃去,得挥发油包合物；将其在50±5℃烘干,制成细粉,即成。该法操作步骤上先采用通过胶体磨乳化、再将乳化液与β-CD以饱和水溶液法包合的制备方法，包合时间明显缩短，且挥发油的利用率和包合率均明显提高，具有生产效率高、产品质量稳定的优点。
86. 102986323 农具滚笼支撑装置
CN
27.03.2013
A01B 35/02 Loading...
A01B 35/02
Loading...
201210342215.2
迪尔公司
肖恩·J·贝克尔
A01B 35/02
Loading...
本发明公开一种用于将滚笼连接到农具的滚笼支撑装置。滚笼支撑装置包括具有轴承座的中心部。周边部围绕轴承座径向地延伸。周边部具有用于连接到具有第一横截面的地面接合杆的径向内部缺口，和用于连接到具有第二横截面的地面接合杆的径向外部缺口。
87. 102985779 热交换器管板、热交换器以及制造热交换器管板的方法
CN
20.03.2013
F28D 7/16 Loading...
F28D 7/16
Loading...
201180031517.1
热矩阵集团有限公司
罗恩·波斯特马
F28D 7/16
Loading...
在一种制造热交换器管板（10）的方法中，密封元件（32）布置在热交换器管（36）的相应端部（34）上。所述热交换器管（36）的具有所述密封元件（32）的所述端部（34）布置在模具（42）的预定位置处。所述热交换器管（36）的所述端部（34）被密封，使得在管板材料的浇铸过程中待浇铸在所述模具（42）中的管板材料不会进入所述热交换器管（36）。管板材料被浇铸在模具（42）中以覆盖所述密封元件（32）。该管板材料在所述模具（42）中硬化。
88. 202776767 一种纸尿裤
CN
13.03.2013
A61F 13/496 Loading...
A61F 13/496
Loading...
201220134608.X
浙江康恩贝健康产品有限公司
张爱翎
A61F 13/496
Loading...
本实用新型涉及一种纸尿裤。它包括透水无纺布内覆层、不透水的防漏外覆层，吸收芯层、合围成裤状的连接件，吸收芯层是多层复合材料体由无尘纸或小白纸或无纺布间夹高分子吸收材料层构成或由高分子吸收材料层与无尘纸或小白纸或无纺布层叠并以无尘纸或小白纸或无纺布包覆而成，或是高分子吸收材料层与木桨纤维和高分子材料混合层层叠并以无尘纸或小白纸或无纺布包覆而成。把高分子吸水材料层层夹在纸状间隔层之间，避免了高分子吸水材料层过厚易自由流动而造成局部聚集厚薄不均甚至局部缺失，而且还能让尿液更容易下排下渗，减少上层高分子吸水材料层接触尿液时间过长后迅速膨胀阻碍尿液下向下传递和扩散，最大限度地发挥高分子吸水材料的吸收作用，并达到锁住尿液的功能。
89. 102947292 含氮杂芳基化合物
CN
27.02.2013
C07D 401/14 Loading...
C07D 401/14
Loading...
201180027950.8
霍夫曼-拉罗奇有限公司
康拉德·辈莱切
C07D 401/14
Loading...
本发明涉及新的式(I)的含氮杂芳基化合物，其中A1、A2、(a)、R1、R2、R3、R4、R5和R6如在说明书和权利要求中所限定，以及其生理学可接受的盐和酯。这些化合物抑制PDE10A并且可以被用作药物。
90. 102786433 Rhizoma corydalis amide compound extract, preparation method and application
CN
21.11.2012
C07C 237/06 Loading...
C07C 237/06
Loading...
201210068581.3
浙江康恩贝制药股份有限公司
王如伟
C07C 237/06
Loading...
The invention relates to the medical chemistry field, and discloses a rhizoma corydalis amide compound extract, a preparation method and an application. The rhizoma corydalis amide compound extract contains a 50%-55% of compound with a structure in a formula (I), wherein a main compound is 2-bromovaleryl chloride-5-acetic ester and butyrylamide-4-acetic ester. The rhizoma corydalis amide compound extract can be used for preparing drugs for treating coronary heart diseases, angina pectoris or myocardial infarction.
91. 102706999 延胡索水溶性非生物碱类化合物的分析检测方法
CN
03.10.2012
G01N 30/88 Loading...
G01N 30/88
Loading...
201210037779.5
浙江康恩贝制药股份有限公司
王如伟
G01N 30/88
Loading...
本发明涉及分析化学和药物化学领域，公开了延胡索水溶性非生物碱类化合物的分析检测方法，其特征在于，包括如下步骤：(1)取延胡索水溶性非生物碱类提取物，高速离心后过滤；(2)取(1)的上清液干燥后经三甲基硅烷化衍生化处理；(3)将步骤(2)的衍生化产物用气相色谱质谱联用方法分析。本发明可简单、快速、准确地检测延胡索中水溶性非生物碱类化合物成分及其含量，对于充分了解传统良药延胡索的化学成分和控制延胡索水溶性提取物的质量有着重要意义，为延胡索的深入开发提供了研究资料，使研究和生产更加安全、有效和质量可控的延胡索新药成为可能。
92. 202446854 一种用于中药挥发油分离收集的装置
CN
26.09.2012
B01D 11/02 Loading...
B01D 11/02
Loading...
201120568307.3
浙江康恩贝制药股份有限公司
胡林水
B01D 11/02
Loading...
本实用新型涉及一种中药挥发油分离收集装置。它由提取罐3、热交换器5、热交换器2、油水分离器1和连接各设备的管道组成，热交换器2为立式盘管式交换器，提取罐3的提取蒸汽排出管4与热交换器2连通，提取蒸汽进入热交换器2前设有控制阀6,在提取罐3与热交换器2之间的提取蒸汽排出管4最高处设置接口装上控制阀7再与热交换器5连接，与热交换器2连通的接口设在提取蒸汽排出管4最低处，提取蒸汽在热交换器2中走管程冷凝后进入油水分离器1。对所需要的单元设备设置和连接进行改变，对管道控制进行了调整，设计了特殊的连通管，在一套装置中就满足了的多种工艺操作的要求，并且具有分离效果好，提取效率高的特点。
93. 102629180 电子表格动作的自然输入
CN
08.08.2012
G06F 3/0488 Loading...
G06F 3/0488
Loading...
201210012142.0
微软技术许可有限责任公司
J·坎贝尔
G06F 3/0488
Loading...
本发明涉及电子表格动作的自然输入。使用不同的手势和动作来与电子表格交互。在操纵电子表格以及在电子表格中执行其它动作时使用手势。例如，手势可用于在电子表格内移动、选择数据、筛选、排序、下钻/上钻、缩放、分行/列、执行撤销/恢复动作等。与设备相关联的传感器也可用于与电子表格交互。例如，加速计可用于在电子表格内移动和执行操作。
94. 202346083 伸缩组合式瓶塞盖
CN
25.07.2012
B65D 39/00 Loading...
B65D 39/00
Loading...
201120450062.4
浙江康恩贝健康产品有限公司
马鹏飞
B65D 39/00
Loading...
本实用新型涉及一种伸缩组合式瓶塞盖。它包括与瓶口相配合的塞筒、与塞筒相连接的顶盖，塞筒内顶盖上还设置有的套管，而该套管上还套装有长度可伸缩的内塞，该伸缩内塞是由弹簧和管帽件所构成，弹簧一端部分容置于管帽件内且与管帽件内腔连接，另一端套箍在套管上；上述的管帽件的底面上还可以开有小孔；上述的内顶盖上塞筒与套箍连接在套管上的伸缩内塞之间还可以设置有套筒。这样的构造形式能有效的抵压压瓶子内的药片和药丸，固定住不会互相摩擦而损坏，并且在内塞的空腔处还能放置干燥剂，让药片和药丸的保持不受潮，而且结构简单，外形完整与普通的瓶塞相似，具有使用可靠，外形美观，效果明显的特点。
95. 102574812 新型苯并咪唑衍生物及它们作为FXR激动剂的用途
CN
11.07.2012
C07D 235/18 Loading...
C07D 235/18
Loading...
201080043283.8
霍夫曼-拉罗奇有限公司
格雷戈里·马丁·本森
C07D 235/18
Loading...
式(I)化合物及其药用盐可以以药物组合物形式使用，其中A、B、R1、R2、R3、R4、R5、n、m和p具有权利要求1中给出的含义。
96. 102511714 一种适合婴幼儿的高活性益生菌组合物及制备方法
CN
27.06.2012
A23L 1/09 Loading...
A23L 1/09
Loading...
201110431997.2
浙江康恩贝健康产品有限公司
吴芝岳
A23L 1/09
Loading...
本发明涉及一种适合婴幼儿食用的高活性的益生菌组合物及制备方法。所述的组合物包括如下重量百分比的活性组分：双歧杆菌0.33-3.3％、麦芽糊精45-60％、葡萄糖10-20％、乳清粉10-20％、益生元5-10％。其制备方法步骤如下：①辅料干燥至水活度(Aw)≤0.1；②用干燥的医用氮气置换混合机内的空气；③先加入少量麦芽糊精，再加入益生菌，混合5分钟，再加入剩余的麦芽糊精，以及其它原辅料均匀后出料。本发明所述的组合物及其制成的功能性食品(包括保健品)，所含的益生菌的菌种和原辅料安全性高且搭配平衡，菌量适当，更适合中国的婴幼儿肠道，具有增强婴幼儿的免疫力、促进肠道健康的作用。
97. 202269368 软胶囊
CN
13.06.2012
A23L 1/29 Loading...
A23L 1/29
Loading...
201120358653.9
浙江康恩贝健康产品有限公司
胡钢亮
A23L 1/29
Loading...
本实用新型涉及一种软胶囊。它由各种食用浓缩剂和包裹食用浓缩剂的胶囊壳所组成，胶囊壳为椭圆体，椭圆体上设置有内腔为锥体状的凸起，该锥体状内腔的锥底侧与椭圆体是相贯的。由于在胶囊体上设置了锥状体的凸起，方便了对胶囊的破口，锥状管式的内腔可以形成多种大小开孔，这样既可以用于液体状内容物的包装也适合膏状和粉粒状内容物的包装。具有开口和孔径大小容易控制，通用性广的优点。
98. 102462586 一种纸尿裤
CN
23.05.2012
A61F 13/531 Loading...
A61F 13/531
Loading...
201010552366.1
浙江康恩贝健康产品有限公司
张爱翎
A61F 13/531
Loading...
本发明涉及一种超薄纸尿裤。它包括透水无纺布内覆层、不透水的防漏外覆层，吸收芯层、合围成裤状的连接件，吸收芯层是多层复合材料体由无尘纸或小白纸或无纺布间夹高分子吸收材料层构成或由高分子吸收材料层与无尘纸或小白纸或无纺布层叠并以无尘纸或小白纸或无纺布包覆而成，或是高分子吸收材料层与木桨纤维和高分子材料混合层层叠并以无尘纸或小白纸或无纺布包覆而成。其吸收芯层中摒弃了木浆、绒毛浆、纸浆，在保证吸收量的前提下，大大降低了产品厚度，提高了使用的舒适性。把高分子吸水材料层层夹在纸状间隔层之间，避免了高分子吸水材料层过厚易自由流动而造成局部聚集厚薄不均甚至局部缺失，而且还能让尿液更容易下排下渗，减少上层高分子吸水材料层接触尿液时间过长后迅速膨胀阻碍尿液下向下传递和扩散，最大限度地发挥高分子吸水材料的吸收作用，并达到锁住尿液的功能。
99. 102448939 烟酰胺衍生物、其制备以及其作为抗癌药物的治疗用途
CN
09.05.2012
C07D 213/82 Loading...
C07D 213/82
Loading...
201080022768.9
赛诺菲
J.阿里冈
C07D 213/82
Loading...
本发明涉及式(I)的烟酰胺衍生物、包含其的组合物、以及它们的治疗用途，具体而言，作为抗癌药物的用途。本发明还涉及制备所述化合物的方法并涉及一些中间体产物。
100. 102441982 在容器处理设施中处理至少一个容器的方法
CN
09.05.2012
B29C 49/24 Loading...
B29C 49/24
Loading...
201110309656.8
克朗斯股份公司
沃尔夫冈·哈恩
B29C 49/24
Loading...
本发明涉及一种在容器处理设施中处理至少一个容器的方法，其包括以下步骤：用标记对一个容器进行标记；探测所述至少一个容器的所述标记；基于所探测到的所述标记来选择所述容器处理设施的至少一个容器处理机器和/或所述容器处理设施的至少一个容器处理机器的至少一个运行设置；以及基于所述至少一个容器处理机器和/或所述至少一个运行设置的选择来处理所述至少一个容器。
101. 102429994 一种复方鱼腥草合剂及其制备方法
CN
02.05.2012
A61K 36/78 Loading...
A61K 36/78
Loading...
201110450252.0
浙江康恩贝中药有限公司
胡江宁
A61K 36/78
Loading...
本发明涉及一种复方鱼腥草合剂及其制备方法，以鱼腥草、金银花、连翘、黄芩、板蓝根为药材，其制备方法包括提取、醇沉、大孔树脂吸附分离和合剂配制，提取采用水蒸气蒸馏法或超临界液体萃取法提取挥发油有效成分，药渣再水煎煮。本发明通过醇沉、大孔树脂洗脱等步骤去除药材中煎煮过程中产生的及本身含有的单糖及多糖成分，合剂配制时不加糖，通过本发明制备的复方鱼腥草合剂含糖量不高于每100ml0.5g，达到无糖产品的要求；且提高了有效指标成分黄芩苷，增加了产品的疗效。
102. 102429995 一种复方鱼腥草合剂的制备方法
CN
02.05.2012
A61K 36/78 Loading...
A61K 36/78
Loading...
201110450624.X
浙江康恩贝中药有限公司
叶剑锋
A61K 36/78
Loading...
本发明涉及复方鱼腥草合剂的制备方法，以鱼腥草、金银花、连翘、黄芩、板蓝根为药材，其制备方法包括煎煮提取、高速机离心、醇沉后再高速机离心、絮凝沉淀和合剂配制。本发明应用高速机离心替代传统的常规过滤，提高了去杂质的效率，絮凝沉淀除去大分子物质，解决了引起复方鱼腥草合剂长期放置后的沉淀问题，制备的复方鱼腥草合剂，在长期放置后不会引起沉淀产生，提高了药品的安全性。
103. 102427852 用于抑制糖皮质素受体(GCR)基因表达的组合物和方法
CN
25.04.2012
A61P 3/10 Loading...
A61P 3/10
Loading...
201080021373.7
霍夫曼-拉罗奇有限公司
雅克·巴伊
A61P 3/10
Loading...
本发明涉及用于GCR基因表达的双链核糖核酸(ds RNA)。本发明还涉及包含所述ds RNA或编码其的核酸分子或载体以及药用载体的药物组合物；使用所述药物组合物治疗由GCR基因的表达导致的疾病的方法；和用于抑制GCR在细胞中的表达的方法。
104. 202193270 透明包装盒
CN
18.04.2012
B65D 25/10 Loading...
B65D 25/10
Loading...
201120251779.6
浙江康恩贝健康产品有限公司
马鹏飞
B65D 25/10
Loading...
本实用新型涉及一种透明包装盒。它透明的盒体、盒盖所组成，盒体由反扣的槽状凸框和与反扣的槽状凸框沿口相连接的盒体底板所构成，盒体底板上设有向上的、间隔排列的凸棱，所述的盒盖由盖板和与盖板相连接下翻的盖框所构成，盖板上设有向下凸出、间隔排列的凹槽，盒盖上间隔排列的凹槽与盒体上间隔排列的凸棱是对应错开的，所述的盒体和盒盖还设有锁扣件它由盒盖盖框上设置的向内凸起，盒体槽状凸框上相对应处设置的匹配凹坑所构成。具有可一次成型，加工容易，有利于盒内物品的多方位展示，盒体有防震、防冲击作用，能有效保护内装物品不受损，包装稳定性好，保证产品在运输过程中不移动位置，减少或者避免产品因为移位或者其他运输时候包装不稳定的原因造成的产品变形、破损的优点。
105. 102405520 用于在玻璃基板上的芯片等级封装的镭射切割的方法
CN
04.04.2012
H01L 21/78 Loading...
H01L 21/78
Loading...
201080017408.X
伊雷克托科学工业股份有限公司
彼得·皮罗高斯奇
H01L 21/78
Loading...
本发明提供一种用于切割复合电子装置的改良方法。复合电子装置藉由将两个或更多基板84、90合并成一含有多个装置12的组装10而制造。本发明提供用于运用镭射处理80以切割复合电子装置12的方法。这些所示方法可提供较少像是基板36、50的裂痕58或碎裂39的缺点，而同时将隙缝142的宽度最小化并维持系统产出量。
106. 102388533 MEMS谐振器
CN
21.03.2012
H03H 3/007 Loading...
H03H 3/007
Loading...
201080016032.0
NXP股份有限公司
约普·M·博恩泰姆普斯
H03H 3/007
Loading...
一种体声学模式MEMS谐振器，包括具有第一物理布图的第一部分以及布图修改特征。所述谐振频率是所述物理布图的函数，其设计为使得所述频率变化对于50nm谐振器形状边缘的边缘位置的偏差来说少于150ppm。这种设计按照以下方式结合了至少两个不同的布图特征，使得小的边缘位置变化(来自于不可控的工艺变化)对谐振频率的影响可以忽略。
107. 102342903 一种护肤组合物及其在预防和延缓皮肤衰老的用途与方法
CN
08.02.2012
A61K 8/97 Loading...
A61K 8/97
Loading...
201110315909.2
浙江康恩贝健康产品有限公司
胡钢亮
A61K 8/97
Loading...
本发明涉及一种化妆组合物及其预防和延缓皮肤衰老的用途与方法。护肤组合物，包括白藜芦醇、茶多酚，其中白藜芦醇∶茶多酚质量分数为＝1-20∶1-20。本发明从整体和平衡的角度出发，多角度多层次地研究皮肤衰老的机制，针对引起衰老的内源性原因和衰老引起的病理变化，同时从提高细胞活性、清除自由基及重塑皮肤结构、调节机体代谢四个方面入手，将几种安全、高效的抗衰老活性物质配伍成组合物，从而使延缓皮肤衰老的效果更显著、安全。
108. 102327244 一种盐酸氨溴索口腔崩解片及其制备方法
CN
25.01.2012
A61K 9/20 Loading...
A61K 9/20
Loading...
201110293404.0
杭州康恩贝制药有限公司
徐春玲
A61K 9/20
Loading...
本发明公开了一种盐酸氨溴索口腔崩解片，所述口腔崩解片包括盐酸氨溴索，所述口腔崩解片由包括以下质量配比的原辅料制成：经包衣制成盐酸氨溴索掩味颗粒以所含盐酸氨溴索计1份，填充剂1～2份，崩解剂0.1～0.25份，矫味剂0.5～1份，凉口剂0.01～0.05份，润滑剂0.029～0.05份，助流剂0.03～0.05份；本发明盐酸氨溴索口腔崩解片崩解效果好，溶出度高，本发明的辅料中加入一定比例凉口剂，有效减轻服药后对口腔和咽喉部产生的不适感，口感好，不良口感持续时间短，在服用后也能够给患者带来能够良好的用药过程，适于工业化生产。
109. 102318827 一种促进神经系统发育的营养素组合物及保健品
CN
18.01.2012
A23L 1/30 Loading...
A23L 1/30
Loading...
201110200029.0
浙江康恩贝健康产品有限公司
孙俊
A23L 1/30
Loading...
本发明涉及一种促进神经系统发育的营养素组合物及保健品，包含营养素，所述的营养素包含DHA和ALA，所述的DHA与ALA的质量比是1∶20～20∶1。不饱和脂肪酸DHA和ALA的组合物，具有促进智力和视力发育的功能，且组合物的功能效果优于单纯补充同量DHA或ALA的效果。组合物中现成的DHA可满足机体对DHA的直接需求，同时ALA也在持续转化成DHA，可满足较长时间内机体对DHA的后续需求，另外ALA亦可激化机体内由ALA向DHA转化所参加的酶的活性，从而使个体在停止摄食的DHA/ALA制品后，提高机体对其他食物来源中的DHA转化合成能力，且这种促进作用可以维持较长的时间。
110. 102313692 对一种或多种材料进行测量的系统及方法
CN
11.01.2012
G01N 15/10 Loading...
G01N 15/10
Loading...
201110130889.1
卢米耐克斯公司
韦恩·D·罗特
G01N 15/10
Loading...
提供了对一种或多种材料进行测量的系统及方法。一种系统被配置为将一种或多种材料从一个或多个贮存容器转移至测量装置的成像空间。另一系统被配置为在测量装置的成像空间中对一种或多种材料成像。一种附加的系统被配置为在测量装置的成像空间中使一种或多种材料大致上固定不动。又一系统被配置为将一种或多种材料从一个或多个贮存容器转移至测量装置的成像空间、在所述成像空间中对所述一种或多种材料成像、在所述成像空间中使所述一种或多种材料或它们的某种组合大致上固定不动。
111. 102266292 Matrix diclofenac potassium sustained-release pellet capsules and production process thereof
CN
07.12.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
201110197866.2
Zhejiang Jinhua Conba Bio-pharm. Co., Ltd.
Jin Qingping
A61K 9/16
Loading...
The invention relates to matrix diclofenac potassium sustained-release pellet capsules and a production process thereof. The matrix diclofenac potassium sustained-release pellet capsules are prepared by filling matrix diclofenac potassium sustained-release pellets into gastric-soluble capsule shells. The matrix diclofenac potassium sustained-release pellets are prepared in one step by extrusion and rolling. The formula of the matrix diclofenac potassium sustained-release pellets comprises basic remedy diclofenac potassium 10-50%, matrix agent 1-20%, diluent 20-80%, antioxidant 0.1-5%, antisticking agent 0.1-5%, absorption promoting agent 1-10%, and any available wetting agent as balance, wherein the matrix agent is hydrophilic gel matrix agent, or hydrophilic gel matrix agent and erodible matrix agent, or hydrophilic gel matrix agent and insoluble matrix agent. The matrix diclofenac potassium sustained-release pellet capsules provided by the invention have the advantages of high bioavailability, long in vivo holdup time, regular drug release, good in vivo (Beagle dogs) absorption and reproducibility, good sustained-release effect, simple production process, short production period, and no flying of dust during production, and are suitable for industrial production.
112. 102231956 Fruit and vegetable snacks
CN
02.11.2011
A23L 1/212 Loading...
A23L 1/212
Loading...
200980148251.1
Frito Lay North America Inc.
Anand Ashish
A23L 1/212
Loading...
The present invention discloses formulations for vacuum baked fruit and vegetable snack pieces that have a crispy, crunchy texture similar to potato chip, corn based wafers, and other popular snack items. A fruit or vegetable base is combined with other ingredients and water to make a slurry, which is sheeted and dried in a vacuum belt dryer, and separated into snack sized pieces. In one embodiment, substantial amounts of solid inclusions are combined with the slurry before drying.
113. 102216457 Compositions and methods for inhibiting expression of factor VII genes
CN
12.10.2011
C12N 15/11 Loading...
C12N 15/11
Loading...
200980145933.7
Hoffmann La Roche
Bramlage Birgit
C12N 15/11
Loading...
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Factor VII gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a Factor VII gene using said pharmaceutical composition; and methods for inhibiting the expression of Factor VII in a cell.
114. 102203089 N-sulfonamido polycyclic pyrazolyl compounds
CN
28.09.2011
C07D 451/00 Loading...
C07D 451/00
Loading...
200980142638.6
Elan Pharm Inc.
Konradi Andrei W.
C07D 451/00
Loading...
The current invention provides compounds having a structure according to Formulae (1), (2), (3), and (4): wherein the A-ring, B-ring, C-ring, m, n, R25, R50, and R51 are as described in the specification. The invention also provides pharmaceutical compositions comprising compounds of Formulae (1), (2), (3), and (4), as well as methods of treating cognitive disorders, such as Alzheimer's disease. The invention further provides intermediates useful in preparing the compounds of Formulae (1), (2), (3), and (4).
115. 102196848 Filter cartridge having a filter within a filter, and an endplate sealing structure on an outer filter element
CN
21.09.2011
B01D 27/08 Loading...
B01D 27/08
Loading...
200980142379.7
康明斯过滤IP公司
A·M·韦尔斯
B01D 27/08
Loading...
A filter within a filter cartridge design is described that includes a sealing structure on an endplate of an outer filter element. Generally, the sealing structure includes an annular flange on the endplate that can directly seal against an interior surface of a housing when the filter cartridge is assembled for use. During filtration, the annular flange prevents a working fluid from bypassing the outer filter element. The sealing flange can seal with the housing in a press fit engagement.
116. 102186830 New benzimidazole derivatives
CN
14.09.2011
C07D 235/18 Loading...
C07D 235/18
Loading...
200980140719.2
Hoffmann La Roche
Benson Gregory Martin
C07D 235/18
Loading...
The invention is concerned with novel benzimidazole derivatives of formula (I) wherein R1 to R6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds can be used as medicaments.
117. 102186856 Pyrrolopyrimidine compounds as cdk inhibitors
CN
14.09.2011
C07D 487/04 Loading...
C07D 487/04
Loading...
200980141314.0
Novartis AG
Besong Gilbert
C07D 487/04
Loading...
The disclosed compounds relate to treatments and therapies for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of cancer, transplant rejections, and autoimmune diseases. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8 and CDK9, using the compounds provided herein.
118. 102164899 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as FXR modulators against dyslipidemia and related diseases
CN
24.08.2011
C07D 231/56 Loading...
C07D 231/56
Loading...
200980137812.8
Hoffmann La Roche
Benson Gregory Martin
C07D 231/56
Loading...
This invention relates to novel indazole or 4,5,6,7-tetrahydro-indazole derivatives of formula (I) wherein R1 to R8 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be used as medicaments. The compounds are selective modulators of the farnesoid-X-receptor, preferably agonists. The farnesoid-X-receptor (FXR) is a member of the nuclear hormone receptor superfamily of transcription factors. Diseases which are affected by FXR modulators include increased lipid and cholesterol levels, particularly high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, diseases of cholesterol absorption, atherosclerotic disease, peripheral occlusive disease, ischemic stroke, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, diabetic nephropathy, obesity, cholesterol gallstone disease, cholestasis/fibrosis of the liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), psoriasis, cancer, particularly gastrointestinal cancer, osteoporosis, Parkinson's disease and Alzheimer's disease. Preferred diseases (and conditions) which are affected by FXR modulators are prevention or treatment of high LDL cholesterol levels, high triglycerides, dyslipidemia, cholesterol gallstone disease, cancer, non-insulin dependent diabetes mellitus and metabolic syndrome. Particularly preferred diseases which arc affected by FXR modulators arc high LDL cholesterol, high triglyceride levels and dyslipidemia.
119. 102164900 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
CN
24.08.2011
C07D 231/56 Loading...
C07D 231/56
Loading...
200980137912.0
霍夫曼-拉罗奇有限公司
格雷戈里·马丁·本森
C07D 231/56
Loading...
This invention relates to novel indazole derivatives of formula (I), wherein R1 to R7 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be use as medicaments. The compounds are selective modulators of the farnesoid-X-receptor, preferably agonists the farnesoid-X-receptor (FXR) is a member of the nuclear hormone receptor superfamily of transcription factors. Diseases which are affected by FXR modulators include increased lipid and cholesterol levels, particularly high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, diseases of cholesterol absorption, atherosclerotic disease, peripheral occlusive disease, ischemic, stroke, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, diabetic nephropathy, obesity, cholesterol gallstone disease, cholestasis/fibrosis of the liver, non alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), psoriasis, cancer, particularly gastrointestinal cancer, osteoporosis, Parkinson's disease and Alzheimer's disease. Preferred diseases (and conditions) which are affected by FXR modulators are prevention or treatment of high LDL cholesterol levels high triglycerides, dyslipidemia, cholesterol gallstone disease, cancer, non-insulin dependent diabetes mellitus and metabolic syndrome. Particularly preferred diseases which arc affected by FXR modulators arc high LDL cholesterol, high triglyceride levels and dyslipidemia.
120. 102149688 New benzimidazole derivatives
CN
10.08.2011
C07D 235/18 Loading...
C07D 235/18
Loading...
200980135308.4
Hoffmann La Roche
Benson Gregory Martin
C07D 235/18
Loading...
The invention is concerned with novel benzimidazole derivatives of Formula (I) wherein A, n and R1 to R7 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds act on Farnesyl X receptor (FXR) and against cholesterol and lipid illnesses, diabetes, obesity, psoriasis, cancer, osteoporosis, Parkinson's and Alzheimer's disease.
121. 102150081 Method and system for producing a Pepper's ghost
CN
10.08.2011
G03B 21/28 Loading...
G03B 21/28
Loading...
200980136703.4
Musion IP Ltd.
O'connell Ian Christopher
G03B 21/28
Loading...
This invention concerns a method of producing a Pepper's Ghost. The method may comprise projecting an image of a subject onto a reflective and transparent screen (7) to create a virtual image (15) of the subject alongside an object (21). The subject of the virtual image may have a colour temperature and the method may comprise illuminating the object (21) with light having a colour and intensity that results in a colour temperature of the object (21) at least approximately matching the colour temperature of the subject of the virtual image. The method may comprise altering the intensity of light that falls on the object (21) by moving the lighting arrangement towards or away from the object (21) whilst maintaining an intensity of light omitted by the lighting arrangement constant. The method may comprise projecting patterns (53) and/or images that would be achieved if the subject was actually present and light was reflected or transmitted by the subject and/or creating a shadow which the subject in the virtual image would make if the subject was actually present. The method may comprise creating two virtual images using the same foil. The method may comprise projecting an image of the subject onto the screen (7) onto a reflective bounce screen (4) and altering a distance between the projector and the reflective bounce screen (4) to move the virtual image.
122. 102143959 Hepatitis C virus inhibitors
CN
03.08.2011
C07D 403/14 Loading...
C07D 403/14
Loading...
200980112993.9
Squibb Bristol Myers Co.
Bachand Carol
C07D 403/14
Loading...
The present disclosure relates to compounds of structure (I), compositions and Methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
123. 102138954 Quality control method of pulean preparation
CN
03.08.2011
G01N 30/88 Loading...
G01N 30/88
Loading...
201010614535.X
Zhejiang Modern Chinese Traditional Medicine and Natural Medicines Research Institute Co., Ltd.
Wu Jian
G01N 30/88
Loading...
The invention provides a quality control method of a pulean preparation. The quality of the pulean preparation is controlled through measuring the content of alpha-linolenic acid in the pulean preparation; the quantity of needed pulean preparation is less; the content of the alpha-linolenic acid can be detected after the primary treatment of the pulean preparation without the purification of alpha-linolenic acid; and as the quantitative measurement is performed on the alpha-linolenic acid through gas chromatography, the test accuracy is high, and the reliability is good. The quality control method is very suitable for industrial application, and can be used for controlling the quality of a drug; and the inner quality of the product can be effectively controlled through the monitoring the alpha-linolenic acid in the pulean preparation.
124. 102106841 Tamsulosin hydrochloride preparation and preparation method thereof
CN
29.06.2011
A61K 9/52 Loading...
A61K 9/52
Loading...
200910155645.1
Hangzhou Conba Pharmaceutical Co.,Ltd.
Wang Ruwei
A61K 9/52
Loading...
The invention relates to a tamsulosin hydrochloride preparation and a preparation method thereof. The preparation comprises the following components in percentage by weight: 0.1 to 2 percent of tamsulosin hydrochloride, 0.5 to 5 percent of lecithin, 55 to 80 percent of filler, 10 to 30 percent of sustained-release matrix agent, and 1 to 10 percent of adhesive matrix agent. The tamsulosin hydrochloride sustained-release capsule preparation prepared by the method can be absorbed in a body more quickly, and acts more quickly, can be used for overcoming the influence of diet on tamsulosin hydrochloride absorption, is more convenient to take, and is suitable for more people.
125. 102106060 Electric maschine in a high protection category with improved rotor cooling
CN
22.06.2011
H02K 1/20 Loading...
H02K 1/20
Loading...
200980128577.8
西门子公司
康拉德·布兰德尔
H02K 1/20
Loading...
An electric machine has a stator (1) and a rotor shaft (3). The rotor shaft (3) is rotatably mounted about a shaft axis (5) in relation to the stator (1), said axis (5) defining an axial direction, a radial direction and a tangential direction. A rotor (6), which is in electrical co-operation with the stator (1), is arranged on the rotor shaft (3). The rotor (6) has at least one continuous axial rotor channel (8). The stator (1) has a lamination stack (10) that extends over the rotor (6) when viewed in the axial direction. The lamination stack (10) completely surrounds the rotor (6) when viewed on a sectional plane that is orthogonal to the axial direction, forming a closed inner rotor chamber (11) when viewed on the sectional plane. A respective cover (14) is provided on both axial sides of the lamination stack (10).; At least one of the covers (14) has a central cavity (15) to allow the passage of the rotor shaft (3). The lamination stack (10) has at least one axial stator channel (12') that runs continuously in the axial direction and that is completely closed when viewed on the sectional plane. The covers (14) are designed in such a way that in conjunction with the lamination stack (10) they form at least one radial channel (16) running in the radial direction. The radial channels (16) connect the axial stator channel(s) (12') to the inner rotor chamber (11) by means of a fluid connection but are otherwise closed. To force convection, an element (17) that acts as a fan is located on the rotor shaft (3) axially within the covers (14).
126. 102099856 Audio encoding/decoding scheme having a switchable bypass
CN
15.06.2011
G10L 19/14 Loading...
G10L 19/14
Loading...
200980127915.6
Fraunhofer Ges Forschung
Grill Bernhard
G10L 19/14
Loading...
An apparatus for encoding comprises a first domain Converter, a switchable bypass, a second domain Converter, a first processor and a second processor to obtain an encoded audio signal having different signal portions represented by coded data in different domains, which have been coded by different coding algorithms. Corresponding decoding stages in the decoder together with a bypass for bypassing a domain Converter allow the generation of a decoded audio signal with high quality and low bit rate.
127. 102058629 Method for producing ginkgo biloba leaf tablets by high-speed tablet press
CN
18.05.2011
A61K 36/16 Loading...
A61K 36/16
Loading...
201010616801.2
浙江康恩贝制药股份有限公司
谭炜
A61K 36/16
Loading...
The invention relates to a method for producing gingko biloba leaf tablets by a high-speed tablet press. In the method, the white tablets with hardness more than or equal to 6kgf are produced by adopting a specific formula consisting of the following components in percentage by weight: 20 to 30 percent of gingko biloba leaf extract, 10 to 20 percent of microcrystalline cellulose, 10 to 15 percent of cane sugar, 34 to 64.9 percent of starch, and 0.1 to 1 percent of magnesium stearate through the following steps of: (1) sucking the starch in the same proportion as the gingko biloba leaf extract, sucking the gingko biloba leaf extract, mixing for 5 minutes, sucking the microcrystalline cellulose and the rest starch, and mixing for 5 minutes; (2) cooking the cane sugar into syrup for later use, and adding 5 to 10 percent of 30-50% ethanol solution according to the situation in use; (3) controlling the temperature of a fluidized bed at 40+/-5 DEG C and the atomization pressure to be more than or equal to 0.2MPa, injecting the prepared syrup, and boiling and granulating; and (4) screening the granules through a 16-mesh screen, and tabletting the material with fine powder proportion between 10 and 20 percent through the high-speed tablet press. By selecting the specific auxiliary formula and the specific process production parameters and control parameters, the raw materials are pre-treated to be a state suitable for the high-speed tablet press, so that the high-speed tablet press can produce the tablets in accordance with the standard quality requirement in China.
128. 102026614 Compositions and methods incorporating photocatalysts
CN
20.04.2011
A61K 8/34 Loading...
A61K 8/34
Loading...
200980117722.2
宝洁公司
埃伦·S·贝克
A61K 8/34
Loading...
The various embodiments provide a composition including an active material having functional groups capable of covalent attachment to a substrate in the presence of an acid or a base, a photocatalyst capable of generating an acid or a base upon exposure to light, and a vehicle. The compositions may also include surfactants, emulsifiers, oxidants, and other components. A method for treating a substrate is also disclosed. The method includes the steps of applying at least one active material having functional groups to the substrate, applying a photocatalyst to the substrate, and exposing the photocatalyst and the at least one active material to light for forming covalent attachments between the functional groups and constituent groups on the substrate. The compositions and methods described herein are useful in personal care product and consumer care product applications, for example.
129. 102015601 Fluoroalkyloxy alkanes, process for production and uses thereof
CN
13.04.2011
C07C 41/16 Loading...
C07C 41/16
Loading...
200880128870.X
Al Chi Mi A. S. R. L.
Conte Lino
C07C 41/16
Loading...
The present invention relates to fluoroalkyloxy alkanes having formula (I) : RF-R1-O-R2 wherein: RF is a linear or branched perf luoroalkyl group, having from 1 to 12, preferably from 2 to 8, carbon atoms; R1 is a linear or branched, non-fluorinated alkylene group, having from 1 to 6, preferably from 2 to 4, carbon atoms,- R2 is a linear or branched, non-f luorinated alkyl group, having from 1 to 12, preferably from 2 to 8, carbon atoms, possibly containing at least one ether bond -O- along the chain. The present invention further relates to a process for preparation and use thereof, possibly in mixture with at least one silicone oil, as medicaments in ophthalmology, in particular as tamponade liquids in an operation for the treatment of retinal detachment.
130. 102014927 Boron-containing small molecules as anti-inflammatory agents
CN
13.04.2011
A61K 31/69 Loading...
A61K 31/69
Loading...
200980116279.7
Anacor Pharmaceuticals Inc.
Sales Marcelo
A61K 31/69
Loading...
Compounds and methods of treating anti-inflammatory conditions are disclosed.
131. 102007122 Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
CN
06.04.2011
C07D 403/14 Loading...
C07D 403/14
Loading...
200880128632.9
百时美施贵宝公司
卡罗尔·巴钱德
C07D 403/14
Loading...
The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.
132. 101998954 Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors
CN
30.03.2011
C07D 403/14 Loading...
C07D 403/14
Loading...
200980113722.5
百时美施贵宝公司
C·巴查德
C07D 403/14
Loading...
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
133. 101998952 Hepatitis c virus inhibitors
CN
30.03.2011
C07D 403/10 Loading...
C07D 403/10
Loading...
200880128704.X
Bristol-Myers Squibb Company
Langley David R.
C07D 403/10
Loading...
The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
134. 101947211 Method for preparing acetylcysteine effervescent tablet
CN
19.01.2011
A61K 9/46 Loading...
A61K 9/46
Loading...
201010271906.9
Zhejiang Jinhua CONBA Bio-pharm. Co., Ltd.
Lu Jihong
A61K 9/46
Loading...
The invention discloses an acetylcysteine effervescent tablet consisting of the following components in percentage by weight: 5 to 35 percent of acetylcysteine, 30 to 70 percent of effervescing agent, 0 to 25 percent of filling agent, 0 to 3 percent of adhesive, 0 to 5 percent of lubricant, 0.5 to 2 percent of sweetener, 0 to 10 percent of aromatic and 0.3 to 2 percent separant. The effervescent tablet adopts a preparation method for packing acid sources or carbon dioxide sources in the effervescing agent by using the separant as simethicone, and solves the problem that the effervescent tablet can easily lose efficacy when laid aside. Compared with the conventional process, the preparation method has the advantages of simple operation, stable quality and suitability for industrial production.
135. 101918243 Reinforced energy absorption device and assembly
CN
15.12.2010
B60N 2/42 Loading...
B60N 2/42
Loading...
200880125320.2
Faurecia Sieges Automobile
Meghira Julien
B60N 2/42
Loading...
A device (2) for absorbing energy by deformation, in particular for a motor vehicle seat (10), in the event of an impact, the energy absorption device (2) comprising: a plate (20) of substantially constant thickness (e) comprising at least a first cutout (12) and a second cutout (14) which are separated by a bridge (16); and a rod (19) extending through the first cutout (14), wherein the bridge (16) comprises a collar (18) having, at least locally, a thickness (E) greater than the thickness (e) of the plate (20).
136. 101902597 User interface for a remote control application
CN
01.12.2010
H04N 5/445 Loading...
H04N 5/445
Loading...
201010135753.5
Universal Electronics Inc.
Smith-Kielland Ingvald Alain
H04N 5/445
Loading...
A hand-held electronic device (1150) having a remote control application user interface that functions to displays operational mode information to a user. The graphical user interface may be used, for example, to setup the remote control application to control appliances for one or more users in one or more rooms, to perform activities, and to access favourites. The remote control application is also adapted to be upgradeable. Furthermore, the remote control application provides for the sharing of operational mode information.
137. 101874786 Aspirin enteric-coated preparation prepared by solvent-free extrusion spheronization method
CN
03.11.2010
A61K 9/16 Loading...
A61K 9/16
Loading...
201010195587.8
Zhejiang Jinhua CONBA Bio-pharm. Co., Ltd.
Jin Qingping
A61K 9/16
Loading...
The invention relates to an aspirin enteric-coated preparation prepared by a solvent-free extrusion spheronization method. The aspirin enteric-coated preparation comprises the following components: drug-containing pills, contagion gown and enteric coating, wherein the drug-containing pills contains 5 to 8.5 parts of aspirin, 1.5 to 5 parts of lipid matrix and 0 to 1 part of release regulator in parts by weight; and the weight of increment of contagion gown accounts for 1-8% of that of the drug-containing pills, and the weight of increment of contagion gown accounts for 5 to 30% of that of the contagion gown pills. The preparation method is as follows in sequence: utilizing an extrusion spheronization method to prepare the drug-containing pills without the absence of water, preparing the contagion gown and the enteric coating, and then filling capsules. A lipin material is utilized as an adhesive and a filling diluent, and the prepared aspirin enteric-coated preparation has good sensitive stability and large drug-loading rate. The in-vitro releasing results of enteric-coated micro-pills show that almost no enteric-coated micro-pills release in a medium with pH of 1.2, while more than 70% of the enteric-coated micro-pills release in 45min in phosphate buffer medium with pH of 6.8, which shows significant enteric-coated characteristics; in-vivo studies of Beagle dogs show that compared with commercially available enteric-coated tablets, the relative bioavailability of the invention is 125.7%. The in-vitro slow-releasing results of enteric-coated micro-pills show that almost no enteric-coated micro-pills release in a medium with pH of 1.2, while significant slow-releasing effect is obtained in phosphate buffer medium with pH of 6.8, and the quality of pills is stable; and in-vivo pharmacokinetic studies of Beagle dogs show that compared with commercially available aspirin slow-releasing enteric-coated tablets, the relative bioavailability of the invention is 112.9%.
138. 101861132 Medical devices having a filter insert for controlled diffusion
CN
13.10.2010
A61F 2/00 Loading...
A61F 2/00
Loading...
200880116271.6
Boston Scient Scimed Inc.
Clarke John
A61F 2/00
Loading...
An implantable or insertable medical device is provided which includes as components: (a) a substrate component comprising a depression that is at least partially filled with a therapeutic agent-containing material (115) that comprises a first therapeutic agent, and (b) a pre-formed filter insert (120) disposed in the depression such that it regulates transport of chemical species between the depression and the exterior of the device upon implantation or insertion of the device in vivo.
139. 101855276 Process for the preparation of a conductive polymer composition
CN
06.10.2010
C08G 61/12 Loading...
C08G 61/12
Loading...
200880115965.8
斯蒂茨丁荷兰聚合物学会
玛丽·赫曼特
C08G 61/12
Loading...
The present invention relates to a process for the preparation of a conductive polymer composition comprising the steps of A) providing a latex containing a conductive polymer; B) mixing the latex from A with either an aqueous latex of a polymer, or with (a) water-soluble precursor(s) of a polymer; C) removing water from the so obtained mixture; D) heating the product from step C) to a temperature at which the polymer added in step B flows or where the polymer introduced in step B is formed from out of its precursor(s); and E) processing and/or solidifying the product of step D) into a desired form, wherein the amount of conductive polymer is between 0.1 and 10 wt% relative to the total of the total of components in step A and B. In step A optionally carbon nanotubes (CNTs) in an aqueous medium are preferably added to the latex containing conductive polymer. In that case the conductive polymer may behave as a conductive polymeric surfactant for the CNTs dispersed in water.
140. 101837071 Composition of plant extracts and application in preventing or treating scars
CN
22.09.2010
A61K 36/82 Loading...
A61K 36/82
Loading...
201010110874.4
浙江康恩贝健康产品有限公司
邵胜荣
A61K 36/82
Loading...
The invention relates to a composition of plant extracts for preventing or treating scars and application in preventing or treating skin scars. The composition comprises the following active ingredients in percentage by weight: 30 to 95 percent of asiaticoside, 4 to 35 percent of licorice root extract and 1 to 35 percent of green tea extract, wherein the composition accounts for 0.5 to 30 percent when applied to preparing external products of skin, and the composition is uniformly mixed with medically-acceptable excipients or carriers in proportion to prepare products in forms of gel, cream, serosity, aqueous solution agents, emulsions or solids. The composition has strong effect of preventing and treating the scars and small dosage under the combined action of the three active ingredients, and can avoid possible phenomena of pruritus and pain in the process of the healing of wound surfaces and reduce allergy rates and inflammation probability greatly, so that the color and luster of the skin at the healing position is more natural. The composition of the plant extracts can be added into medicaments or cosmetics for preventing or treating the scars by a known method used by technical personnel in the field, and is convenient to use.
141. 101836944 Composition of plant extracts and application in skin whitening and moisture preservation
CN
22.09.2010
A61K 8/97 Loading...
A61K 8/97
Loading...
201010110875.9
Zhejiang CONBA Healthy Products Co., Ltd.
Hu Gangliang
A61K 8/97
Loading...
The invention relates to a composition of plant extracts and application thereof in skin whitening and moisture preservation. The composition comprises the following active ingredients in percentage by weight: 5 to 90 percent of green tea extract, 5 to 50 percent of ginkgo leaf extract and 5 to 45 percent of centella extract, wherein the composition accounts for 0.5 to 20 percent when applied to preparing external products of skin, and the composition is uniformly mixed with medically-acceptable excipients or carriers in proportion to prepare products in forms of gel, cream, serosity, aqueous solution agents, emulsions or solids. The composition has the effects on skin whitening and moisture preservation without adding moisture preserving components; compared with products with similar application, the composition has stronger effects on skin whitening and moisture preservation and smaller dosage; the composition is safe, has no toxic or side effect, has low allergy rates and inflammation probability, penetrates into skin dermis, does not change the normal apoptosis process of cells, restrains tyrosinase, dopachrome tautomerase, DHICA oxidase and endothelin appropriately and balances the metabolism of melanin, so that the color and luster of the skin is more natural; and in addition, the generated skin whitening effect is definite, and the composition is convenient to use in cosmetics.
142. 101821258 Novel preparation process
CN
01.09.2010
C07D 401/14 Loading...
C07D 401/14
Loading...
200880111400.2
Boehringer Ingelheim Int
Schnaubelt Juergen
C07D 401/14
Loading...
The present invention relates to a process for preparing compounds of the general formula I in which R1 and R2 are defined as mentioned in the description, the pharmaceutically acceptable salts thereof and the solvates thereof, which can be prepared starting from compounds of the general formula II in which R1 is defined as mentioned in the description.
143. 101772302 Boron-containing small molecules
CN
07.07.2010
A01N 55/08 Loading...
A01N 55/08
Loading...
200880101464.4
安纳考尔医药公司
S·J·贝克
A01N 55/08
Loading...
This invention provides, among other things, novel compounds useful for treating bacterial infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
144. 101759645 P38 inhibitors and methods of use thereof
CN
30.06.2010
C07D 231/56 Loading...
C07D 231/56
Loading...
200910266076.8
阵列生物制药公司
马克·芒森
C07D 231/56
Loading...
The compounds are represented by the formula, wherein Y, A, W, B, U, V, X and Ar1have the meanings given in the specification, and are useful in therapy as p38-inhibitors. Such compounds are generally called 2-aza-[4.3.0]bicyclic heteroaromatic ring, and are useful as therapeutic substances of diseases which can be treated by inhibition of a p38 signaling pathway.
145. 101755344 A photovoltaic apparatus having a filler layer and method for making the same
CN
23.06.2010
H01L 31/048 Loading...
H01L 31/048
Loading...
200880014736.7
Solyndra Inc.
Beck Markus E.
H01L 31/048
Loading...
Devices for converting light into electric current are provided. A representative device has an encasing structure having at least one portion transparent. The encasing structure is configured to pass light energy into an interior of the encasing structure. The device further has a photovoltaic device positioned within the interior of the encasing structure. The photovoltaic device is positioned to receive light energy. The photovoltaic device is operable to transform the light energy into electric current. The device further has a protective space material, disposed between the encasing structure and the photovoltaic device. The protective space material is operable to transmit the light energy. The protective space material is a non-solid material having a physical property such as a viscosity of less than 1 x 10<6> cP and/or a thermal coefficient of expansion of greater than 500 x 10<-6> / DEG C.
146. 101754966 Hepatitis c virus inhibitors
CN
23.06.2010
C07D 413/14 Loading...
C07D 413/14
Loading...
200880025131.8
百时美施贵宝公司
卡罗尔·巴钱德
C07D 413/14
Loading...
The present disclosure relates to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein A and B are each phenyl; D and E are each five-membered aromatic rings containing one, two, or three i hcteroatoms independently selected from nitrogen, oxygen, and sulfur; provided that, at least one of D and E is other than imidazole; compositions and methods for the treatment of Hepatitis C virus (HCV) inf ection. Also disclosed are pharmaceutical compositions containing such compounds and methods f or using these compounds in the treatment of HCV inf ection.
147. 101716151 Finasteride oral tablets with quick dissolution and preparation method thereof
CN
02.06.2010
A61K 9/20 Loading...
A61K 9/20
Loading...
200910155644.7
Hangzhou Conba Pharmaceutical Co., Ltd.
He Houhong
A61K 9/20
Loading...
The invention relates to finasteride oral tablets with quick dissolution and a preparation method thereof. The preparation is prepared by taking finasteride as a raw material medicament and adding auxiliary materials such as a filling agent, a disintegrant, a surfactant, an adhesive, a lubricant and the like. The adopted formula and preparation process not only ensure that the content uniformity of the preparation is easy to meet the requirement, but also ensure that the finasteride in the tablets can be quickly disintegrated and dissolved out in water, thereby greatly improving the dissolution of the medicament and playing a role in treatment more effectively.
148. 101641162 Method and apparatus for the surface modification of flat substrates
CN
03.02.2010
B05C 3/18 Loading...
B05C 3/18
Loading...
200880006347.X
Rena GMBH (DE)
Kaltenbach Konrad
B05C 3/18
Loading...
The invention relates to a method and to an apparatus for coating substrates within the context of producing thin-film solar cells or modules made of glass, metal or plastic with metallic compounds, such as, for example, cadmium sulphide or zinc sulphide using a liquid (F) which is located in a treatment basin (3) and the chemical constituents of which can be deposited on the substrate surface bysuitable temperature control and with the formation of a permanent film, in which the under side of the substrate, which side is to be coated, is heated, which is necessary in order to form the desired film, by means of a suitable heating means (11) which is capable of heating the substrate (2) to the required temperature without the upper side which is not to be treated being wetted during the treatment with a heating liquid and without the substrate (2) being held or protected from above.
149. 101627978 Glipizide sustained-release capsule formulation and preparation method thereof
CN
20.01.2010
A61K 9/62 Loading...
A61K 9/62
Loading...
200910101053.1
Hangzhou Conba Pharmaceutical Co., Ltd.
Hu Jiangning
A61K 9/62
Loading...
The invention relates to a glipizide sustained-release capsule formulation and a preparation method thereof. The glipizide sustained-release capsule formulation contains three glipizide sustained-release pillers with different release periods, wherein the glipizide sustained-release pillers respectively include conventional glipizide sustained-release pillers and glipizide time-delay sustained-release pillers in the following percentage by weight: 20-80 percent of the glipizide sustained-release pillers, 10-50 percent of glipizide 4-hour time-delay sustained-release pillers and 5-30 percent of glipizide 8-hour time-delay sustained-release pillers. A release curve of the glipizide sustained-release capsule formulation is more similar to a physiological change curve of the blood sugar concentration of human bodies, and release peaks of glipizide are respectively generated after the glipizide sustained-release capsule formulation is orally taken, 4 hours later and 8 hours later, corresponding to three meals a day, which are orally taken by ordinary people, thereby better controlling the blood sugar levels, reducing the blood sugar fluctuation of diabetics and bringing better treatment effect to patients.
150. 101624391 Thiophene derivatives as antiviral agents for flavivirus infection
CN
13.01.2010
C07D 333/38 Loading...
C07D 333/38
Loading...
200910139375.5
Virochem Pharma Inc.
Chan Chun Kong Laval
C07D 333/38
Loading...
The present invention provides novel compounds represented by formula I: or pharmaceutically acceptable salts thereof useful for treating flaviviridae viral infection.
151. 101618116 Method for preparing blood-nourishing angelica capsules by using powder coatings
CN
06.01.2010
A61K 36/804 Loading...
A61K 36/804
Loading...
200810062672.X
Zhejiang Conba Pharmaceutical Co., Ltd.
Huang Zhengbiao
A61K 36/804
Loading...
The invention relates to a method for preparing blood-nourishing angelica capsules by using powder coatings, which comprises the following steps: crushing a blood-nourishing angelica extract bulk medicament into 16 to 60 meshes; putting the crushed bulk medicament into a fluid bed; adjusting the inlet temperature to between 50 and 70 DEG C and the spraying pressure to between 100 and 400 kPa; spraying an alcohol-soluble coating agent of which the weight is 1.5 to 4 percent of that of the bulk medicament; when the coating agent is sprayed out, stopping spraying liquid and continuously drying the mixture for 20 to 60 minutes; and taking the mixture out and filling the mixture into capsules. The blood-nourishing angelica capsules aim at the characteristics of the blood-nourishing angelica extract bulk medicament powder to select the alcohol-soluble coating agent (Colorcon OY-C-7240 type coating agent) with the best matching property so as to perform adhesion on the bulk medicament powder and coat a layer of thin film coat outside the powder, thereby not only reducing the moisture absorption surface area of the powder and holding back the entering of moisture, but also increasing the fluidity of the medicinal powder. Besides, the original extraction process of the medicament and the medicament composition are not changed, and the effect of the products is not influenced.
152. 101618126 Analgesic antiphlogistic gel and preparation method thereof
CN
06.01.2010
A61K 9/00 Loading...
A61K 9/00
Loading...
200810062671.5
Zhejiang Conba Pharmaceutical Co., Ltd.
Huang Zhengbiao
A61K 9/00
Loading...
The invention relates to an analgesic antiphlogistic gel and a preparation method thereof. The gel comprises the following raw materials: wild celery, raw rhizoma arisaematis, raw radix aconiti feri, honeylocust, mirabilite, menthyl salicylate, borneol, carbomer 940, ethanol, polyethylene glycol 400 and nautisan. The preparation method comprises the following steps: breaking up the wild celery, the raw radix aconiti feri, the raw rhizoma arisaematis and the honeylocust, soaking and decocting the mixture with water, and performing filtration, concentration, cryoprecipitation and filtration on the decoction; taking glycerine and ethanol and proper amount of purified water, stirring the materials evenly and then adding the mirabilite into the mixture, stirring the mixture evenly to dissolve the mirabilite, adding the carbomer, and standing and swelling the mixture to prepare a gel base material; and adding a liquid medicament, the menthyl salicylate, the borneol, the polyethylene glycol 400 and the nautisan into the gel base material, adjusting the pH to between 5.3 and 6.7, stirring the mixture evenly, and filling the mixture to obtain the analgesic antiphlogistic gel. Because talc powder with the most dosage in auxiliary materials of the base material is removed, the concentration of the effective components carried by the auxiliary materials with the same volume is greatly improved, and the medicament dosage volume is reduced, thus the analgesic antiphlogistic gel not only reduces the preparation cost and the transportation cost, but also is convenient for patients to use.
153. 101612140 Preparation method of diclofenac potassium sustained-release pellet capsule
CN
30.12.2009
A61K 9/58 Loading...
A61K 9/58
Loading...
200910100649.X
Zhejiang Jinhua Conba Bio-Pharm. Co., Ltd.
Jin Qingping
A61K 9/58
Loading...
The invention relates to a preparation method of diclofenac potassium sustained-release pellet capsule. The preparation method sequentially comprises: preparing diclofenac potassium hormone pill by an extrusion-spheronization mothod, packing an isolation layer, packing a sustained-release layer and encapsulating the capsule, extruding the capsule into a stick on the condition that the set frequency of an extruder is 10-100Hz, and spheronizing the capsule for 3-30min on the condition that the frequency of a spheronization machine is 20-150Hz. In the invention, flying dust does not occur, the pollution is little and the production process meets the requirement of GMP; after the prepared diclofenac potassium sustained-release capsule is taken orally, the plasma concentration of the drug is gentle with small fluctuation and the capsule has good sustained-release effect.
154. 101585845 Preparation process of Mezlocillin
CN
25.11.2009
C07D 499/68 Loading...
C07D 499/68
Loading...
200910098463.5
Zhejiang Jinhua Conba Biopharmaceutical Co., Ltd.
Jin Qingping
C07D 499/68
Loading...
The invention relates to a preparation process of Mezlocillin, which reacts Ampicillin trihydrate with 1-chlorocarbonyl-3-methylsulfonyl-2-imidazolidinone in water phase under alkaline condition and then proceeds acidified crystallization, filtration, washing and drying in acetone/water, or alcohol/water, or isopropanol/water system to obtain Mezlocillin. The Mezlocillin prepared by the inventive method can reach 95%-97% of molar yield, 0.06%-0.4% of organic residual quantity, more than 98.5% of dry basis content, less than 0.4% of single impurity, less than 1.5% of total related substances and good quality, is particularly suitable for direct lyophilization in water-phase salt formation to obtain high-quality Mezlocillin sodium for injection of medicinal product, and has prominent economical and social benefits.
155. 101585844 Preparation process of Azlocillin
CN
25.11.2009
C07D 499/68 Loading...
C07D 499/68
Loading...
200910098462.0
Zhejiang Jinhua Conba Biopharmaceutical Co., Ltd.
Jin Qingping
C07D 499/68
Loading...
The invention relates to a preparation process of Azlocillin, which subjects Ampicillin and imidazole chloride to condensation reaction in water phase and then prepares Azlocillin by crystallization in isopropanol/water system. The Azlocillin is obtained by filtration and drying. The inventive process for preparing Azlocillin uses isopropanol/water crystallization system, which is not reported in documents, for crystallization, crystalline particles are appropriate in size and suitable for industrial mass production, and meanwhile, the product is high in yield and purity to thereby improve the quality of Azlocillin, and the quality stability is good.
156. 101588957 Display and operating device for electronic trailer systems, and method for the configuration of the display and operating device
CN
25.11.2009
B62D 63/00 Loading...
B62D 63/00
Loading...
200880002187.1
Wabco GmbH
Constabel Lars
B62D 63/00
Loading...
The invention relates to a display and operating device (12) for electronic trailer systems of a trailer vehicle (1), comprising at least the following: a housing (15) for fastening in or on the trailer vehicle (1), a vehicle-internal interface (17) for connecting to a vehicle-internal data line (10), an internal memory (21) for storing configuration data (D1) of control units (4, 8) of the trailer vehicle (1) recorded via the vehicle-internal interface, a control unit (20) for querying the configuration data by the user, a display device (23) for displaying the configuration data (D1) to the user, a control unit (19) for starting a configuration, recording the configuration data (D1) via the vehicle-internal interface (17), storing it in the internal memory (21) and displaying the configuration data on the display device (23), an energy storage device (18) for autonomous power supply, and a power supply connection (22) for connecting to a vehicle-internal power supply, wherein the display and operating device (12) automatically records and stores the configuration data (D1) via the vehicle-internal interface (17).
157. 101580547 Hasylated polypeptides, especially hasylated erythropoietin
CN
18.11.2009
C07K 17/10 Loading...
C07K 17/10
Loading...
200910133235.7
弗雷泽纽斯卡比德国有限公司
阿拉尔德·S·康拉德特
C07K 17/10
Loading...
The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS moecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO).
158. 101569640 Application of total asiaticoside to preparation of medicaments or cosmetics for preventing and curing striae gravidarum
CN
04.11.2009
A61K 36/23 Loading...
A61K 36/23
Loading...
200810061519.5
Zhejiang Conba Health Products Co., Ltd.
Shao Shengrong
A61K 36/23
Loading...
The invention relates to an application of total asiaticoside to the preparation of medicaments or cosmetics for preventing and curing striae gravidarum. The total asiaticoside and a medically acceptable excipient or carrier are mixed in a weight ratio of (0.1 to 30): (70 to 99.9) to prepare cream, ointment, emulsion, gel, astringent, and the like. The total asiaticoside and the medically acceptable excipient or carrier are mixed in a weight ratio of (1 to 20): (80 to 89), and the sum of asiaticosid and madecassoside is larger or equal to 40 percent; by applying the characteristic that the healed skin has complete functions by firstly restoring the damaged skin corium and then restoring the epidermis due to asiatic centella extracts capable of reaching the skin corium by the devitalized tissue, the asiatic centella extracts start to be applied to the healing of the skin corium in the middle period of pregnancy so as to provide a regeneration environment for the damaged skin corium. In-situ stem cells in the skin corium dermis tissue are started to heal the damaged elastic fibers and collagen fibers in time so as to increase the elasticity of the corium dermis tissue and prevent or lessen the generation of the striae gravidarum.
159. 101573117 Bifeprunox doses for treating schizophrenia
CN
04.11.2009
A61K 31/496 Loading...
A61K 31/496
Loading...
200780032002.7
Solvay Pharm BV
Barbato Luigi M.
A61K 31/496
Loading...
The present disclosure is directed to a daily dose of bifeprunox for the treatment of a patient with schizophrenia. Such dose is effectively used in methods for treating schizophrenia comprising administering to a patient a pharmaceutical composition comprising an effective amount of at least one bifeprunox compound, amongst other effects, resulting in a reduction of side effects associated with schizophrenia treatment such as: no weight gain, improvement of non-fasting triglyceride levels and/or total cholesterol levels. Treatment effects are e.g. a reduction of PANSS total score in a patient and an increase of the time to deterioration of schizophrenia and improvement of psychotic symptoms.
160. 101568515 Resin composition suitable for (re) lining of tubes, tanks and vessels
CN
28.10.2009
C07C 69/54 Loading...
C07C 69/54
Loading...
200780047548.X
帝斯曼知识产权资产管理有限公司
乔安娜·克莱恩纳格沃尔特
C07C 69/54
Loading...
The present invention relates to structural, radically curable resin compositions suitable for (re)lining containing a. 30-70 wt.% of a resin characterized by (i) a molecular weight Mn between 500 and 3000 and (ii) an acid value between 0 and 30 mg KOH/g resin, and wherein at least 80 % of the total amount of resin is vinyl ester resin, b. 30-70 wt.% of at least one reactive diluent, characterized in that at least 25% of the reactive diluent is a difunctional diluent having a molecular weight Mn between 200 and 500 and the optional monofunctional diluent having a molecular weight Mn between 100 and 200, c. 0.00001-5 wt.% initiator, d. 0.00001-5 wt.% inhibitor further characterized in that the average molecular weight per reactive unsaturation (WPU) of the components (a) and (b) is equal or greater than 190 Dalton and that the amount of styrene in the resin composition is less than 5 wt.% (calculated as wt.% of the total weight of the components (a), (b), (c) and (d)).
161. 101558059 Hepatitis c virus inhibitors
CN
14.10.2009
C07D 401/14 Loading...
C07D 401/14
Loading...
200780037723.7
Bristol-myers Squibb Company
Bachand Carol
C07D 401/14
Loading...
The present disclosure relates to a compound of Formula (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
162. 101543521 Rape pollen soft capsule and method for preparing same
CN
30.09.2009
A61K 36/31 Loading...
A61K 36/31
Loading...
200910098151.4
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Jiqiang
A61K 36/31
Loading...
The invention relates to a rape pollen soft capsule and a method for preparing the same. The content of the soft capsule consists of a rape pollen extract and an auxiliary material, wherein the rape pollen extract is a mixture of a fat-soluble extract and a water-soluble extract of rape pollen; the auxiliary material consists of a diluent, an antioxidant, a suspending agent and an emulsifier; based on a standard capsule, a liquid medicine in each capsule contains 0.1 to 0.6 gram of the extract, 0.1 to 0.4 gram of the diluent, 0.02 to 0.06 gram of the emulsifier, 0.02 to 0.04 gram of the suspending agent and proper amount of the antioxidant; and the method comprises the steps of pouring the liquid medicine into a soft capsule machine, pelleting, shaping, cleaning the capsule, and drying the capsule in a drying room to obtain the rape pollen soft capsule. The rape pollen soft capsule has the effect of tonifying the kidney and consolidating vital essential and is applied to preventing and treating kidney qi instability, soreness and weakness of waist and knees, insufficient micturition or incontinence, chronic prostatitis and prostate hyperplasia. Compared with the prior dosage forms of Prostate-Health and PuLeAn tablet, the rape pollen soft capsule has the advantages of obviously reducing the dose for a patient, improving the curative effect and the bioavailability of the medicament and the like.
163. 101530417 Application of mulberry skin glucoside in preventing and treating hyperuricemia and gout
CN
16.09.2009
A61K 31/7034 Loading...
A61K 31/7034
Loading...
200910095839.7
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Jiqiang
A61K 31/7034
Loading...
The invention discloses a new application of medicine or health care food which employs compound mulberry skin glucoside to prevent or treat hyperuricemia and gout and a medicine or health care food composition with the compound as an active ingredient for preventing and treating hyperuricemia and gout. The compound mulberry skin glucoside with the chemical construction being 3-(2-(4-(beta-D-grape pyran glycosyl group-oxygen-2-hydroxyphenyl))-(E)-ethylene)-5-hydroxyphenyl-beta-D-grape pyranoside can be applied to preparing medicine or health care food for preventing and treating hyperuricemia and gout. The mulberry skin glucoside can be extracted from plants, traditional Chinese medicinal materials or prepared slices of Chinese crude drugs containing the compound or be obtained by means of chemosynthesis. The medicine or health care food preparation prepared with the compound as an active ingredient for preventing and treating hyperuricemia and gout can be applied independently or applied in combination with acceptable excipient of pharmacy to prepare preparation formulations such as mulberry skin glucoside oral liquid, capsule, troche, granular formulation and targeting preparation and the like.
164. 101534829 Hepatitis c virus inhibitors
CN
16.09.2009
A61K 31/501 Loading...
A61K 31/501
Loading...
200780037710.X
百时美施贵宝公司
C·巴查德
A61K 31/501
Loading...
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
165. 101528232 Hepatitis C virus inhibitors
CN
09.09.2009
A61K 31/506 Loading...
A61K 31/506
Loading...
200780037399.9
Squibb Bristol Myers Co.
Bachand Carol
A61K 31/506
Loading...
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
166. 101518356 Method for sterilizing pollen
CN
02.09.2009
A23L 3/36 Loading...
A23L 3/36
Loading...
200910046540.2
Zhejiang Conba Pharmaceutical Co., Ltd.
Liu Shupeng
A23L 3/36
Loading...
The invention relates to a method for sterilizing pollen, which belongs to the technical field of biological medical product preparation processes. The method adopts a method combining microwave heating sterilization, deep refrigeration and drying to sterilize the pollen, which not only can keep the color and the components of the pollen unchanged and maintain the nutrient content of the pollen, but also make the final content of microorganisms lower than the requirement stated by the national standard. The method has the characteristics of performing heating and sterilization for two times at a higher microwave power and a lower microwave power respectively; besides, the microwave heating temperature is controlled well to be not more than 90 DEG C so as to keep the nutrient content unchanged and effectively kill the microorganism in the pollen.
167. 101502526 Application of mulberry twig flavone and diphenyl ethylene extract in preventing or treating hyperuricemia symptoms and uarthritis
CN
12.08.2009
A61K 31/7034 Loading...
A61K 31/7034
Loading...
200910095836.3
Zhejiang Conba Pharmaceutical Co., Ltd.
Kong Lingdong
A61K 31/7034
Loading...
The invention discloses the components of mulberry branch flavone and stilbenes extract and a novel application thereof. According to the results of animal experiments, the mulberry branch flavone and stilbenes extract has no obvious effect on inhibiting the uric acid in the normal blood of normal animals, but reducing the uric acid in the blood of hyperuricemia model animals, thereby ensuring good safety. By compounding the mulberry branch flavone and stilbenes extract with relevant auxiliary materials, medicaments or health-care food and the combination of the medicaments or the health-care food with the compound being the active component for curing and controlling hyperuricemia and uarthritis can be prepared on the basis of the conventional preparation method, and have stable curative effect, are safe and reliable.
168. 101502527 Application of mulberroside in preparing medicament for inhibiting uric acid reabsorption transporter
CN
12.08.2009
A61K 31/7034 Loading...
A61K 31/7034
Loading...
200910095837.8
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Jiqiang
A61K 31/7034
Loading...
The invention discloses a novel application of a mulberroside-A compound in the preparation of drugs for inhibiting uric acid re-absorption transporters, and a combination with the active component being the mulberroside-A compound for preparing the drugs for inhibiting the uric acid re-absorption transporters, so that the mulberroside-A compound with the chemical structure being 3-[2-[4-(Beta-D-glucopyranosyl-oxygen-2-hydroxyphenyl)]-(E)-ethenyl]-5-hydroxyphenyl-Beta-D-glucopyranoside is applicable in the preparation of the drugs for inhibiting the uric acid re-absorption transporters. The mulberroside-A can be either extracted from plants, traditional Chinese medicinal materials and traditional Chinese medicinal decoction pieces containing the mulberroside-A, or obtained through chemical synthesis. The drug preparation for inhibiting the uric acid re-absorption transporters can be either prepared separately from the mulberroside-A compound as the effective component or combined with pharmaceutically acceptable excipient, and further prepared into the drug forms of mulberroside-A, such as oral liquid, capsules, tablets, granules, targeting preparations and the like on the basis of the conventional preparation method.
169. 101502563 Application of mulberry twig flavone and diphenyl ethylene extract in preparing medicament for inhibiting uric acid reabsorption transporter
CN
12.08.2009
A61K 36/605 Loading...
A61K 36/605
Loading...
200910095840.X
Zhejiang Conba Pharmaceutical Co., Ltd.
Kong Lingdong
A61K 36/605
Loading...
The invention discloses components of flavonoids of mulberry branches and extracts of stilbenes and a new purpose thereof. Animal test results show that the flavonoids of mulberry branches and the extracts of stilbenes have exact inhibition effect for a uric acid reabsorption transporter with abnormally increased animal expression of a hyperuricemia model, but no significant inhibition effect for the expression of the uric acid reabsorption transporter at the normal level of a normal animal, thereby having good safety. The flavonoids of mulberry branches and the extracts of stilbenes can be prepared into a drug for inhibiting the uric acid reabsorption transporter together with the related pharmaceutical excipients by the conventional preparation method, and a pharmaceutical composition for inhibiting the uric acid reabsorption transporter prepared by taking the compound as an active ingredient can be used for treating the diseases which are related to the abnormal high expression of the uric acid reabsorption transporter.
170. 101496834 Preparation method of mulberry twig flavone and diphenyl ethylene extract
CN
05.08.2009
A61K 36/605 Loading...
A61K 36/605
Loading...
200910095838.2
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Jiqiang
A61K 36/605
Loading...
The invention relates to a method for preparing a ramulus mori flavone and diphenyl ethylene extract. The ramulus mori flavone and diphenyl ethylene extract is obtained by a hydroalcoholic method and elution through a macroporous polymeric adsorbent column. The content of diphenyl ethylene compounds is between 30 and 70 weight percent and the content of flavone compounds is between 30 and 70 weight percent as measured by ultraviolet spectrophotometry and an HPLC method by adoption of mulberroside and Quercetin-3-O-beta-D-mannopyranoside as index compositions. The invention provides a novel method for preparing the ramulus mori flavone and diphenyl ethylene extract.
171. 101491509 Cyclovirobuxine-D sustained-release micro-pill capsules and preparation method thereof
CN
29.07.2009
A61K 9/50 Loading...
A61K 9/50
Loading...
200810162802.7
Hangzhou Ethypharm-Conba Chinese Traditional Medicine R&D Center Co., Ltd.
Wang Ruwei
A61K 9/50
Loading...
The invention relates to a buxine slow-release micro-pill capsule and a method for preparing the same. A slow-release micro-pill consisting of a hollow pill core, a main drug layer using Cyclovirobuxine D as an active ingredient and slow-release preparation auxiliary material layer is encapsulated into a capsule to prepare the buxine slow-release micropill capsule; the hollow pill core, the Cyclovirobuxine D as a main drug and the slow-release preparation auxiliary materials comprise the following weight percent: 70 to 95 percent of the hollow pill core, 1 to 5 percent of the Cyclovirobuxine D and the 4 to 25 percent of the slow-release preparation auxiliary materials; and the slow-release preparation auxiliary materials comprise acrylic resin as an adhesive, ethyl cellulose as a coating material, dibutyl sebacate as a plasticizer and talcum powder as a lubricant for encapsulation. The method has good repeatability; and the buxine slow-release micro-pill capsule has even products, good slow release effect and high bioavailability.
172. 101467960 Terbinafine hydrochloride emulsifiable paste and preparation method thereof
CN
01.07.2009
A61K 9/06 Loading...
A61K 9/06
Loading...
200710164858.1
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Linshui
A61K 9/06
Loading...
The invention relates to a self-emulsified terbinafine hydrochloride cream and preparation method thereof, comprising, main medicaments, terbinafine hydrochloride of 0.5-3%, TEFOSE63 (polyethylene glycol-7 stearate) of 6-18%, span 80 of 1-6%, glycerin monostearate of 1-5%, and light liquid petrolatum of 1-4%; the remainder being purified water. Self-emulsifier, surfactant and solvent are heated to 75-80 DEG C, rapidly stirred for 30-45 minutes after complete dissolution, and cooled to around 40 DEG C; maintaining the temperature, the terbinafine hydrochloride is added and stirred continuously; triethanolamine of proper amount is added to regulate the pH value between 4-6, vacuumized, and continuously stirred to the room temperature to obtain the cream with good brightness, good coating ability, less consistency change with the environmental temperature change, good stability and transdermal absorption. Compared with the traditional preparation technology, the preparation method thereof is simple in operation, low in the energy consumption and low in device investment.
173. 101466710 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CN
24.06.2009
C07D 417/06 Loading...
C07D 417/06
Loading...
200680052264.5
Bayer Healthcare LLC
Zhang Zhonghua
C07D 417/06
Loading...
This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
174. 101455648 Puerarin freeze-drying preparation
CN
17.06.2009
A61K 9/19 Loading...
A61K 9/19
Loading...
200910095310.5
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Jiqiang
A61K 9/19
Loading...
The present invention relates to a lyophilized preparation of puerarin which is composed of lipidosome of cardiovascular drug puerarin and pharmaceutically acceptable carrier. The lipidosome of cardiovascular drug puerarin is composed of puerarin, lipidosome component, surfactant and freeze-drying supporting agent, wherein the weight ratio of puerarin, lipidosome component, surfactant and freeze-drying supporting agent is 1:50-40:0.1-1.5:0.1-1. The lipidosome component is dimyristica lecithin and cholesterol. The weight ratio between the dimyristica lecithin and cholesterol is 20-2:1. The surfactant is polysorbate-80. The freeze-drying supporting agent selects mannitol. The lyophilized preparation of puerarin of the invention has the advantages of high enveloping rate, good stability, excellent solubility, and evident reduced hemolytic adverse reaction of puerarin.
175. 101460506 Thiazolyldihydroindazole derivatives as protein kinase inhibitors
CN
17.06.2009
C07D 513/04 Loading...
C07D 513/04
Loading...
200780020848.9
Boehringer Ingelheim Int
Mcconnell Darryl
C07D 513/04
Loading...
The present invention comprises compounds of the general formula (1) in which R<1> to R<6> are each as defined in claim 1 which are suitable for treatment of disorders which are characterized by excessive or abnormal cell proliferation, and their use for producing a medicament with the aforementioned properties.
176. 101443335 Thiazolyl dihydro-indazoles
CN
27.05.2009
C07D 513/04 Loading...
C07D 513/04
Loading...
200780017541.3
Boehringer Ingelheim Int
Steurer Steffen
C07D 513/04
Loading...
The invention relates to compounds of general formula (1), wherein R<1> to R<5> are defined as indicated in claim 1. Said compounds are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation. Also disclosed is the use of the inventive compounds for producing a medicament that has said properties.
177. 101426636 Apparatus and method for producing a large-area fibre-composite structural component
CN
06.05.2009
B29C 70/38 Loading...
B29C 70/38
Loading...
200780013814.7
Airbus GmbH
Schendel Joerg
B29C 70/38
Loading...
The present invention provides an apparatus and a method for producing a large-area fibre-composite structural component, in particular for the aircraft sector, comprising a predetermined shaping element (1) , a controllable laying device (4, 5, 6) for the defined laying of at least one fibrous sheet (15) over or into the predetermined shaping element (1) , a controllable turning device (10) for a defined turning of the predetermined shaping element (1) and of the laying device (4, 5, 6} in relation to each other by a predetermined turning angle, and a central control device, which is connected to the laying device (4, 5, 6) and the turning device (10) for controlling of the same.
178. 101395149 New amines
CN
25.03.2009
C07D 401/12 Loading...
C07D 401/12
Loading...
200780007949.2
Actelion Pharmaceuticals Ltd.
Bezencon Olivier
C07D 401/12
Loading...
The invention relates to novel amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.
179. 101395135 New primary amines
CN
25.03.2009
C07D 213/64 Loading...
C07D 213/64
Loading...
200780007573.5
Actelion Pharmaceuticals Ltd.
Bezencon Olivier
C07D 213/64
Loading...
The invention relates to novel primary amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.
180. 101380650 Method for attaching a sensor at an exhaust gas treating device
CN
11.03.2009
B21C 37/29 Loading...
B21C 37/29
Loading...
200810214390.7
Eberspaecher J. GmbH & Co.
Kontz Markus
B21C 37/29
Loading...
The present invention relates to a method for installing a probe (6) on an exhaust gas treatment device (1), which has at least one ceramic insert (3) secured in a metallic housing (2) by means of a bearing mat, with which a receptacle opening (7) for receiving the probe (6), penetrating through the housing (2) and the bearing mat (5) and into the insert is created when the insert (3) has already been inserted into the housing (2) and secured there with the bearing mat (5).
181. 101379033 Secondary amines
CN
04.03.2009
C07D 211/70 Loading...
C07D 211/70
Loading...
200780004352.2
Actelion Pharmaceuticals Ltd.
Bezencon Olivier
C07D 211/70
Loading...
The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.
182. 201180243 双块式无碴轨道施工用横梁
CN
14.01.2009
E01B 29/06 Loading...
E01B 29/06
Loading...
200720191149.8
南车洛阳机车有限公司
顾青
E01B 29/06
Loading...
本实用新型公开的双块式无碴轨道施工用横梁是在一根主截面为矩形的横梁(1)的上端面设置有四套相同结构的球形定位组件(2)，两端设置角形支撑座(3)，在角形支撑座的下端面均设置半球形定位件，其中一端的支撑座上的半球形定位组件为固定端(4)，另一端支撑座上的半球形定位组件可调为活动端(5)，在横梁中部设置有与固定架实现定位的导向装置(7)、底部设置有座板(6)。本实用新型是双块式无碴轨道施工中保证轨枕铺设精度的重要部件之一，其既起到支撑固定架和轨枕组的作用，又可实现与支脚及固定架之间的精确定位，从而保证了轨枕的铺设质量。同时通过多个横梁的连续架设和交替移动保证了轨枕铺设作业的连续进行。
183. 101341487 Browsing stored information
CN
07.01.2009
G06F 17/30 Loading...
G06F 17/30
Loading...
200680048448.4
Bose Corporation
Olcott Andrew
G06F 17/30
Loading...
A geographical field is displayed including indicia, representing respective items stored in a navigation system, that are displayed in positions that correspond to geographic relationships of the items on the geographic field. In response to a user manipulating a user interface control device, a visible feature of the geographic field is altered to indicate browsing with respect to a predetermined succession of the stored items.
184. 201172497 抽屉式包装盒
CN
31.12.2008
B65D 5/38 Loading...
B65D 5/38
Loading...
200820082779.6
浙江康恩贝健康产品有限公司
王奕
B65D 5/38
Loading...
本实用新型涉及一种抽屉式包装盒，它主要包括内盒和外盒，外盒的侧壁一端敞口，内盒套装于外盒之中，内盒的外形与外盒相匹配，内盒上侧壁为敞口，盒内设有上凸的支撑，支撑上还设有与储放物外形相嵌合的凹坑或开孔。由于在内盒中增设了用于固定存储物品的支撑，外拉此端设有了抽拉内盒的拉手，解决了存储物在其中因搬运会发生位置改变的问题，既不需要增加固定的托垫，又增加了内盒的强度，而且内外盒套合后，因为内盒上有了可供着力的拉手，这样不但开启方便，盒子也不会损坏，而外盒上开设透明视窗或窥视孔，便于消费者观察内装的物品，可以不打开包装即能看清内置商品的，增加了展示功能。
185. 101316625 Neuropeptide-2 receptor-agonists
CN
03.12.2008
A61P 3/10 Loading...
A61P 3/10
Loading...
200680044377.0
Hoffmann La Roche
Conde-Knape Karin
A61P 3/10
Loading...
Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
186. 101317077 Temperature measurement tube
CN
03.12.2008
G01K 1/12 Loading...
G01K 1/12
Loading...
200680044131.3
Areva Nc
Brun Patrice
G01K 1/12
Loading...
A temperature measurement tube is composite and comprises a rigid shaft (1), which is cooled so as to shield it from corrosion and from the melt, and an end-fitting (15) housing a thermocouple (9) on the end of the tube and constructed from a nobel metal, which is resistant to corrosion and to the high melting point. An alumina coating (13) is placed between the two metals in order to prevent any corrosion-inducing electrochemical exchange between them.
187. 101306983 Process for recovering ethanol in gruffs
CN
19.11.2008
C07C 31/08 Loading...
C07C 31/08
Loading...
200810060420.3
Zhejiang Conba Pharmaceutical Co., Ltd.
Bao Jianwei
C07C 31/08
Loading...
The invention relates to a method for reclaiming ethanol in medicine residue. The method comprises the steps of reclaiming through dry process and reclaiming through wet process; firstly, the reclaiming through the dry process is carried out: a steam valve which leads to an extraction tank is opened; steam is led to the bottom of the medicine residue for water steam distillation and ethanol reclaiming; the distilled ethanol passes through a cooling system and enters a storage tank; after a concentration of the distilled ethanol is equal to or slightly lower than a concentration of the used and extracted ethanol by ten percent, heating is stopped; then, the reclaiming through the wet process is carried out: drinking water or steam condensation water at a temperature of between 50 and 80 DEG C is added from the bottom of the extraction tank till immerging the surface of the medicine residue; the steam valve which leads to a jacket is opened; the residual ethanol is reclaimed by adopting peripheral heating and boiling maintenance under the condition of normal atmosphere or micro-vacuum; and the distilled ethanol passes through the cooling system and enters the storage tank; when the concentration of the distilled ethanol is between 2 and 10 percent, the heating is stopped and the ethanol reclaiming is finished. The method has high reclaiming rate, realizes the repeated use and the maximum reclaiming of the ethanol, changes waste into valuable and quite meets the need of national energy conversation and emission reduction. Compared with the prior reclaiming method, the method reduces the reclaiming time by 3 to 6 hours, thereby reducing the reclaiming cost.
188. 201151859 双块式无碴轨道施工设备之支脚
CN
19.11.2008
E01B 35/00 Loading...
E01B 35/00
Loading...
200720191152.X
南车洛阳机车有限公司
袁其刚
E01B 35/00
Loading...
本实用新型公开了一种双块式无碴轨道施工设备之支脚，其包括底座、垫板，在底座的上部设置有中空的底座连接固定管和上座，底座连接固定管底部与底座连接，在底座连接固定管内设置设置有螺杆；上座由连接管和水平定位板构成，水平定位板位于连接管的顶部，连接管的下部位于底座连接固定管内并和螺杆连接，在水平定位板的上部设置有横向调整板和纵向调整板，纵向调整板设置在横向调整板上，在纵向调整板的上部设置有调整球座；在螺杆的下部设置有锥齿轮，在底座连接固定管下部设置有可旋转的齿轮轴，在旋转齿轮轴上位于底座连接固定管内的一端设置有旋转锥齿轮，其和螺杆的下部设置的锥齿轮相互啮合。其结构简单、使用方便，可保证测量和施工精度。
189. 201151858 双块式无碴轨道施工用固定架
CN
19.11.2008
E01B 29/06 Loading...
E01B 29/06
Loading...
200720191154.9
南车洛阳机车有限公司
顾青
E01B 29/06
Loading...
本实用新型公开的双块式无碴轨道施工用固定架由两根纵向梁(2)和两根横向梁(1)构成框架结构，其中一根横向梁的一端位于一根纵向梁的外侧，另一根横向梁的一端位于另一根纵向梁的外侧，在每根横向梁的两端均设置有短柱(3)并使短柱位于横向梁的外侧，从而使四个短柱相对于框架中心对称设置；其中一根纵向梁(2)两端的短柱均设置有起支承作用的平块(6)，另一端纵向梁(2)两端的短柱上均设置有起定位作用的V形块(5)；在每根纵向梁的底部设置有多组用于固定、定位轨枕的支腿(4)，在支腿的下端均连接有脚板。本实用新型既是轨枕的固定装置，又可保证轨枕的精确定位。
190. 201151857 双块式无碴轨道施工设备之手动调整横梁
CN
19.11.2008
E01B 29/06 Loading...
E01B 29/06
Loading...
200720191151.5
南车洛阳机车有限公司
袁其刚
E01B 29/06
Loading...
本实用新型公开了一种双块式无碴轨道施工设备之手动调整横梁，其包括内梁(5)、外梁(4)以及钢轨座(3)、升降螺杆(1)，内梁(5)设置在外梁(4)的下方，钢轨座(3)设置在外梁(4)的两端，升降螺杆(1)设置在内梁(5)的两端，其上部伸出外梁(4)，在外梁(4)的上部设置有锁紧调整座(7)，内梁(5)的上部固定有连接块(13)，锁紧调整座(7)和连接块(13)通过调整螺栓(8)连接。本实用新型结构简单，使用方便。使用本装置，完全可以替代机器的操作，并能够保证达到铺设轨枕时所要求的精度。
191. 201151854 双块式无碴轨道施工设备之回收车
CN
19.11.2008
E01B 29/00 Loading...
E01B 29/00
Loading...
200720191156.8
南车洛阳机车有限公司
顾青
E01B 29/00
Loading...
本实用新型公开的双块式无碴轨道施工设备之回收车由主动车(1)和从动车(2)构成，主动车和从动车均为框架结构，通过连接销(12)连接；在主动车上设置有发电机组(3)、电气柜(11)和液压起重机(6)，在主动车的四角均设置有由减速电机驱动的可双向行走的主动轮组(4)，在从动车两侧中部设置有从动轮组(5)。本实用新型实现上述目的采用的技术方案是：其由主动车和从动车构成，主动车和从动车均为框架结构，通过连接销连接；在主动车上设有作为整个回收车动力源的发电机组、电气柜和液压起重机，在主动车的四角均设置有可双向行走的主动轮组，由减速电机驱动，在从动车两侧中部设置有从动轮组。
192. 101283565 Device interface architecture and protocol
CN
08.10.2008
H04L 29/06 Loading...
H04L 29/06
Loading...
200680037437.6
Qualcomm Inc.
Shah Keyur C.
H04L 29/06
Loading...
An interface architecture and protocol are provided for transferring messages between a plurality of devices. The architecture provides the capability to generate a plurality of service messages according to a single message format, and to transfer the service messages between a plurality of control points (101, 102 and 103) or service entities (114 and 115) according to an efficient multiplexing protocol. The control points can be software applications or device drivers running on a terminal equipment device (118), and the service entities can be communication services such as network access services or device management services running on an attached data communication device (119) such as a modem or a cellular phone.
193. 101266410 Method for confirming front feeding transfer function, lithographic apparatus and device manufacturing method
CN
17.09.2008
G03F 7/20 Loading...
G03F 7/20
Loading...
200810009480.2
ASML Netherlands BV
Baggen Mark Constant Johannes
G03F 7/20
Loading...
In a lithographic apparatus, a feedforward transfer function of a control system, is determined by: a) iteratively learning a feedforward output signal of the control system by iterative learning control for a given setpoint signal; b) determining a relation between the learned feedforward output signal and the setpoint signal; and c) applying the relation as the feedforward transfer function of the control system. A learned feedforward, which has been learned for one or more specific setpoint signals only, can be adapted to provide a setpoint signal dependent feedforward output signal. The learned feedforward can be made more robust against setpoint variations.
194. 101254459 Reinforced regeneration method of big-hole adsorption resin
CN
03.09.2008
B01J 20/34 Loading...
B01J 20/34
Loading...
200810060421.8
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Jiqiang
B01J 20/34
Loading...
A method for the reinforcement and the regeneration of macroporous adsorbent resins is provided. The method includes the following steps: loading an aged resin into a resin column with upper and lower stainless steel sieves provided with 120 meshes at a diameter/high ratio of 1:1-1:3, washing with purified water at a flow rate of 1m<3>/h per ton of resins until the eluate is colorless, back-washing with compressed air or purified water for 3-5 times in the washing process, washing again with 0.1-5.0% hypochloric acid or hypochlorite solution at a flow rate of 1m<3>/h per ton of resins until the eluate is colorless, further washing with purified water at flow rate of 1m<3>/h per ton of resins until the pH value of the eluate is 7 or reaches a pre-determined value, optionally neutralizing the hypochloric acid or hypochlorite residues in resin with 0.5-3.0% hydrochloric acid solution at a flow rate of 0.5-1.5 m<3>/h per ton of resins and washing with purified water until the pH value is 7. The hypochloric acid or hypochlorite solution is sodium hypochlorite and has a concentration of 1.0-3.0% preferably. The inventive method has the advantages of easy operation, low cost, good regeneration effect and waster reutilization.
195. 101254220 Production process of water soluble ginkgo leaf extractive
CN
03.09.2008
A61K 36/16 Loading...
A61K 36/16
Loading...
200810060422.2
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Jiqiang
A61K 36/16
Loading...
A production process of a water soluble ginkgo leaf extract comprises the following steps of pulverizing ginkgo leaf, and extracting with ethanol for 2-4 times to obtain concentrated solution I; diluting with purified water, filtering to obtain medicinal liquid II, washing the residue with purified water for several times, filtering the supernatant to obtain medicinal liquid III, mixing with the medicinal liquid II, diluting with water, and filtering to obtain clear medicinal liquid IV; adsorbing with macroporous adsorptive resin, pre-washing with purified water or ethanol, and eluting with ethanol to obtain medicinal liquid V; concentrating the medicinal liquid V to obtain alcohol-free concentrated extract VI; extracting the concentrated extract VI with ethanol for 2-4 times, filtering, and concentrating the filtrate to obtain concentrated extract VII; or alternatively completely dissolving conventional ginkgo leaf extract in ethanol, recovering ethanol to obtain concentrated extract, extracting with ethanol for 2-4 times, filtering, and concentrating the filtrate to obtain concentrated extract VII; and extracting the concentrated extract VII with purified water for 2-4 times, cooling the extractive solution, filtering, concentrating, and drying to obtain the water soluble ginkgo leaf extract. The inventive production process has the advantages of simple process, stable product quality, and good economic benefit.
196. 101254219 Concentrating method of ginkgo leaf extract
CN
03.09.2008
A61K 36/16 Loading...
A61K 36/16
Loading...
200810060419.0
Zhejiang Conba Pharmaceutical Co., Ltd.
Hu Jiqiang
A61K 36/16
Loading...
A concentrating method for ginkgo leaf extract comprises the following steps of: (1) pulverizing dried ginkgo leaf to 10-20 mesh powder, and extracting with water, methanol or ethanol solution; (2) filtering the extractive solution, adsorbing with macroporous adsorptive resin, and eluting with methanol or ethanol solution; (3) pumping the eluate into a polymer film with nanometer scale, running for 2-3 minutes to keep medicinal liquid passing through the system, turning on a pressurizing pump, regulating a liquid inlet valve, and controlling various parameters of the film; and turning on a flushing valve at the same time turning off a feeding valve to flush the system with the permeate solution; and (4) respectively collecting retentate and permeating solvent, and continuing cycling the retentate to pass through the polymer film with nanometer scale until the consistency of the medicinal liquid meets the requirement. And the following steps of: regulating the flow rate of the inlet flow and outlet flow of a condenser and controlling the temperature of the medicinal liquid below 50 DEG C can be optionally performed before the step (4). The inventive method has the advantages of low energy consumption, high efficiency, ensured quality, and reduced cost.
197. 101245579 Installation unit of double-block non-slag rail construction equipment
CN
20.08.2008
E01B 29/06 Loading...
E01B 29/06
Loading...
200710304859.1
China South Locomotive & Rolling Stock Luoyang Locomotive Co., Ltd.
Sun Huatao
E01B 29/06
Loading...
The invention discloses a car body (1) of an installation unit of the construction equipment of double-block ballastless tracks, which can move along the paved formwork of the tracks. The car body is characterized in that: a clamp (12) of cross beams is arranged on the car body and connected with a cross beam crane (11) in a hanging way; the cross beams (19) are hung and positioned on a supporting foot to be constructed by the clamp (12) of the cross beams; a vibrating grid (9) is arranged on the car body and connected with a crane (17) of the vibrating grid; a fixing frame integrated with sleeper groups is hung on the adjacent cross beam by the vibrating grid through a clamping mechanism (61); short columns (46) at both ends are contacted and connected with the cross beams; the spherical positioning elements (20) on the upper surfaces of the two cross beams are positioned through a V-shaped block (48) at the bottom of the short column at one end and a flat block (49) at the bottom of the short column at the other end; groups of sleepers connected below the fixing frame are vibrated to enter the upper layers of unconsolidated concrete. The car body has the advantages of effectively improving working efficiency and guaranteeing the positioning accuracy of the sleepers.
198. 101245578 Cross-sleeper loading unit and operation mode for double-block non-slag rail construction equipment
CN
20.08.2008
E01B 29/06 Loading...
E01B 29/06
Loading...
200710304858.7
China South Locomotive & Rolling Stock Luoyang Locomotive Co., Ltd.
Yuan Qigang
E01B 29/06
Loading...
The invention belongs to the construction technology and mechanical equipment of the railways, and provides a sleeper loading unit for the construction equipment of the double-block ballastless tracks, wherein the main body of the sleeper loading unit is a bodywork which can move along the laid working tracks; the main body is arranged behind a sleeper installation unit of the whole construction equipment but at the front part of a disassembly unit; cross beams and fixing frames provided by the disassembly unit are received, and sleepers to be paved are stored; the sleepers are front-and-back arranged and positioned at interval, and then are connected with the fixing frames at fixed positions; the cross beams and the sleepers which is connected with the fixing frames are conveyed to a hoisting position, and then supplied to the sleeper installation unit. The sleeper loading unit for the construction equipment of the double-block ballastless tracks has the advantages of realizing the front-and-back linkage between the installation unit and the disassembly unit of the equipment, providing assembly, installation and transportation for the pavement of the sleepers, scientific design, rational and concise structure, and reasonable and compact working procedures of operation process.
199. 101240745 Internal combustion engine using opposed pistons
CN
13.08.2008
F02B 75/32 Loading...
F02B 75/32
Loading...
200710300249.4
Mechanical Innovation Inc. A. Fl
Beverly Gene
F02B 75/32
Loading...
The invention discloses a combustion cylinder of an internal combustion engine, comprising: a first component restricted by a first hollow pipe including a predetermined length, the size and shape of the first hollow pipe are equipped to adapt to contain at least one piston performing reciprocating movement inside the hollow pipe, the first hollow pipe restricts a combustion chamber with high thermal coefficient of expansion and low heat conductivity; mixture of the fuel and the air can be introduced into the combustion chamber for compression and ignition; a second component including the high thermal coefficient of expansion and high heat conductivity and adjacent to the first component; a third component provided around the first hollow pipe and including the combustion chamber which includes low thermal coefficient of expansion and low heat conductivity and is adjacent to the first hollow pipe.
200. 101230060 Substitutional piperidines
CN
30.07.2008
C07D 413/12 Loading...
C07D 413/12
Loading...
200810009976.X
Speedel Experimenta AG
Herold Peter
C07D 413/12
Loading...
SP-P2140 ATE - 132 - Abstract Novel substituted piperidines of the general formula (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent.

